The Use and Abuse of Mutual-Support Programs in Drug Courts by Gordon, Sara
Scholarly Commons @ UNLV Law 
Scholarly Works Faculty Scholarship 
2017 
The Use and Abuse of Mutual-Support Programs in Drug Courts 
Sara Gordon 
University of Nevada, Las Vegas -- William S. Boyd School of Law 
Follow this and additional works at: https://scholars.law.unlv.edu/facpub 
 Part of the Courts Commons, Criminal Law Commons, and the Health Law and Policy Commons 
Recommended Citation 
Gordon, Sara, "The Use and Abuse of Mutual-Support Programs in Drug Courts" (2017). Scholarly Works. 
1030. 
https://scholars.law.unlv.edu/facpub/1030 
This Article is brought to you by the Scholarly Commons @ UNLV Law, an institutional repository administered by 
the Wiener-Rogers Law Library at the William S. Boyd School of Law. For more information, please contact 
david.mcclure@unlv.edu. 
GORDON.DOCX (DO NOT DELETE) 8/7/2017 10:39 AM 
 
1503 
THE USE AND ABUSE OF MUTUAL-
SUPPORT PROGRAMS IN DRUG 
COURTS 
Sara Gordon* 
There is a large gap between what we know about the disease of 
addiction and its appropriate treatment, and the treatment received by 
individuals who are ordered into treatment as a condition of partici-
pation in drug court. Most medical professionals are not appropriate-
ly trained about addiction and most addiction treatment providers do 
not have the education and training necessary to provide appropriate 
evidence-based services to individuals who are referred by drug 
courts for addiction treatment. This disconnect between our under-
standing of addiction and available addiction treatment has wide-
reaching impact for individuals who attempt to receive medical care 
for addiction in this country, as well as for those individuals who are 
compelled by a drug court to receive that treatment. Instead of receiv-
ing evidence-based treatment, most drug court participants are re-
ferred to mutual-support groups and programs based largely or en-
tirely on 12-step principles. Mutual-support groups, while well-
intentioned and helpful as a supplement to evidence-based addiction 
treatment, are not a substitute for scientifically valid addiction treat-
ment and should not constitute the primary form of medical assis-
tance received by drug court participants. 
This Article argues that drug and other specialty courts can be 
part of the transformation of the public perception of addiction, as 
well as the integration of addiction treatment into mainstream medi-
cine by incorporating and endorsing evidence-based strategies for the 
treatment of addiction, including psychosocial and pharmacological 
treatments. Moreover, by adopting these treatments more readily and 
providing more opportunities for drug court participants to receive 
evidence-based treatment, drug courts can dramatically improve 
treatment outcomes for participants. 
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I. INTRODUCTION 
So this purports to be a disease, alcoholism? A disease like a cold? 
Or like cancer? I have to tell you, I have never heard of anyone being told 
to pray for relief from cancer. So what is this? You’re ordering me to 
pray? Because I allegedly have a disease? I dismantle my life and career 
and enter nine months of low-income treatment for a disease, and I’m pre-
scribed prayer?1 
Keep coming back. It works if you work it.2 
 
In 1934, at the height of the Great Depression, William Wilson was 
an unemployed stockbroker and a heavy drinker. Wilson had tried to 
stop drinking before, but his early experiences with alcohol had “pro-
duced in him instant feelings of completeness, invulnerability, and an ec-
stasy that approached the religious,”3 and he had been unable to quit. 
Wilson’s friend, Ebby Tharcher, had been encouraging Wilson to join the 
Oxford Group, a “religious organization bent on creating a moral rea-
lignment in America by facilitating spiritual rebirth through miraculous 
conversion experiences.”4 Tharcher believed that his involvement with 
                                                                                                                                      
 1. DAVID FOSTER WALLACE, INFINITE JEST 180 (1986).  
 2. 12 Step Recovery Slogans, THE RECOVERY GROUP, http://www.therecoverygroup.org/ 
slogans.html (last visited May 30, 2017). 
 3. LANCE DODES & ZACHARY DODES, THE SOBER TRUTH: DEBUNKING THE BAD SCIENCE 
BEHIND 12-STEP PROGRAMS AND THE REHAB INDUSTRY 17 (2014). Wilson had also struggled with 
depression, tobacco use, and other compulsive behaviors. “Even after he stopped drinking, he was still 
a heavy consumer of cigarettes and coffee. He had a sweet tooth, a large appetite for sex, and a major 
enthusiasm for LSD and, later, for niacin, a B-complex vitamin.” Id. at 15. 
 4. Id. at 17–18; see also ERNEST KURTZ, NOT–GOD: A HISTORY OF ALCOHOLICS ANONYMOUS 
17 (1979) (describing how Ebby explained the Oxford group to Wilson: “its non-denominational na-
ture; the importance of taking stock of oneself, confessing one’s defects, and the willingness to make 
restitution; that one could choose one’s own concept of ‘God’—after using the term once, Bill noted, 
Ebby spoke instead of ‘another power’ or a ‘higher power.’”). 
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the group and his own religious and spiritual conversion had been re-
sponsible for his own sobriety, and he thought the group could also help 
Wilson.5 
Wilson initially dismissed Tharcher’s recommendations to join the 
Oxford Group and instead entered into detoxification treatment for the 
fourth time at a hospital in New York City where he was given a detoxi-
fication treatment known as “the belladonna cure.”6 Belladonna, which 
induces visual and auditory hallucinations, was thought to “successfully 
and completely remove[] the poison from the system and obliterate[] all 
craving for drugs and alcohol.”7 Tharcher again visited Wilson in the 
hospital and urged him to give up alcohol and turn his life over to God. 
As Wilson later described to attendees at the “Alcoholics Anonymous 
Comes of Age” Convention in 1955, he finally took this advice and cried 
out “If there is a God, let Him show Himself! I am ready to do anything, 
anything!”8 In response to this outburst, Wilson saw a great white light 
and became “caught up into an ecstasy which there are no words to de-
scribe.”9 Wilson, or Bill W. as he became known to his friends and sup-
porters, never drank again.10 The following year, he founded Alcoholics 
Anonymous (“AA”) and based the group’s famous 12 steps “on the be-
liefs of the evangelical Oxford Group, which taught that people were 
sinners who, through confession and God’s help, could right their 
paths.”11 
And, as we now know, however he came about it, Wilson was onto 
something. As one author put it, “AA filled a vacuum in the medical 
world, which at the time had few answers for heavy drinkers.”12 At the 
                                                                                                                                      
 5. Kurtz describes the scene when Tharcher visits Wilson at Wilson’s home: 
On a dank, cold afternoon in late November 1934, two men sat kitty-corner at the kitchen table of 
a brownstone house at 182 Clinton Street, Brooklyn, New York . . . . The visitor, neatly groomed 
and bright-eyed, smiled in gentle but pained mirth as he surveyed the scene; his tall, thin, craggy-
faced host laughed a bit too loudly, anxious less over his careless attire and the patches of whisk-
ers on his quickly shaved face than at the announcement his friend, an old drinking-buddy, had 
just made:  
  “No thanks, I don’t want any. I’m not drinking.” 
  “No drink? Why not? Are you on the water wagon?” 
  “No, I don’t mean that. I’m just not drinking today.” 
  ‘“Not drinking today!’ Ebby, what’s gotten into you?” 
  “Well, I don’t need it anymore: I’ve got religion.” 
KURTZ, supra note 4, at 7.  
 6. The “belladonna cure” included atropine and scopolamine, both known hallucinogens. 
DODES & DODES, supra note 3, at 19. 
 7. Howard Markel, An Alcoholic’s Savior: God, Belladonna or Both?, N.Y. TIMES (Apr. 19, 
2010), http://www.nytimes.com/2010/04/20/health/20drunk.html?_r=0. 
 8. KURTZ, supra note 4, at 19. 
 9. Id. at 19–20. Wilson describes his feelings in greater detail in the Big Book: “There was utter 
confidence. I felt lifted up, as though the great clean wind of a mountain top blew through and 
through. God comes to most men gradually, but His impact on me was sudden and profound.” BILL 
W., ALCOHOLICS ANONYMOUS 23–24 (Dover Publ’g Inc. 2011). 
 10. DODES & DODES, supra note 3, at 18. 
 11. Gabrielle Glaser, The Irrationality of Alcoholics Anonymous, THE ATLANTIC (Apr. 2015), 
http://www.theatlantic.com/magazine/archive/2015/04/the-irrationality-of-alcoholics-anonymous/ 
386255/. 
 12. Id. 
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time Wilson was struggling with alcohol in the 1930s, alcoholics, and in-
deed all substance abusers, were thought to lack the moral conviction to 
overcome their addictions.13 By the 1950s, the American Medical Associ-
ation had classified alcoholism as a disease, but there were few available 
treatments beyond detoxification in state psychiatric hospitals.14 As Wil-
son’s ideas spread and became popular, even the medical establishment 
began to adopt them; hospitals began creating “alcohol wards,” and AA 
members began to visit patients in the hospital and invite them to AA 
meetings.15 
AA achieved legal recognition in 1970, when United States Senator 
Harold Hughes, an AA member and Democrat from Iowa, persuaded 
Congress to pass the Comprehensive Alcohol Abuse and Alcoholism 
Prevention, Treatment, and Rehabilitation Act (“Hughes Act”).16 This 
Act established the National Institute on Alcohol Abuse and Alcoholism 
(“NIAAA”) and provided funding for the study of alcoholism and its 
treatment.17 Following the passage of the Hughes Act, private insurers 
began recognizing alcoholism as a disease, and treatment became cov-
ered under medical insurance.18 This led to the rapid proliferation of pri-
vate, for-profit rehabilitation centers around the United States, in what 
would soon “become a multibillion dollar industry.”19 Today, there are 
more than 13,000 rehabilitation centers throughout the United States, 
the majority of which use some variation of a 12-step model.20 
And while AA and other 12-step models remain well-known and 
ubiquitous forms of addiction treatment, since Wilson’s time, researchers 
have learned a tremendous amount about the disease of addiction and its 
appropriate treatment. We now know that addiction is a complex brain 
disease, one that affects nearly 16% of Americans over the age of 
twelve.21 This astounding number—over forty million people—is more 
                                                                                                                                      
 13. See Alcoholics Anonymous, WORLD ENCYCLOPEDIA (Nov. 8, 2016), http://www.newworld 
encyclopedia.org/entry/Alcoholics_Anonymous (last modified Nov. 8, 2016). 
 14. Glaser, supra note 11. 
 15. Id. 
 16. Id. 
 17. In turn, the NIAAA “funded [the] nonprofit advocacy group, the National Council on Alco-
holism, to educate the public. The nonprofit became a mouthpiece for AA’s beliefs, especially the im-
portance of abstinence, and has at times worked to quash research that challenges those beliefs.” Id. 
 18. Id. 
 19. Id. (“Hughes became a treatment entrepreneur himself, after retiring from the Senate.”); see 
also Eric Pace, Harold Hughes, Iowa Trucker Turned Politician, Dies at 74, N.Y. TIMES (Oct. 25, 1996), 
http://www.nytimes.com/1996/10/25/us/harold-hughes-iowa-trucker-turned-politician-dies-at-74.html 
(“In 1981, he went back to Iowa. He became an executive with Iowa Realty in Des Moines and also 
opened the Harold Hughes Center, for the treatment of alcoholism, in a Des Moines suburb. The cen-
ter is now known as Gateway and is based at Des Moines General Hospital.”). 
 20. See infra notes 158–67. 
 21. NAT’L CTR. ON ADDICTION & SUBSTANCE ABUSE COLUMBIA UNIV., ADDICTION 
MEDICINE, CLOSING THE GAP BETWEEN SCIENCE AND PRACTICE i (2012) [hereinafter CASA 
REPORT]. 
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than the number of people with heart disease, diabetes, or cancer.22 An 
additional 31.7%, or 80.4 million people, engage in the risky use of addic-
tive substances in ways that threaten their health, safety, or the safety of 
others.23 Moreover, we know that addiction is a chronic disorder, “a per-
sistent [illness] which requires ongoing professional treatment and man-
agement.”24 
Yet unlike almost every known disease or illness—from physical 
conditions like diabetes, to mental illnesses like depression and schizo-
phrenia—there are few guidelines governing the treatment of addiction, 
and addiction is instead treated in a “separate and unrelated system of 
addiction care that struggles to treat the disease without the resources or 
the knowledge base to keep pace with science and medicine.”25 In fact, 
our treatment of addiction in this country has not changed significantly in 
the last century. One reason Wilson and AA were so quickly accepted by 
mainstream medical professionals is that they had very few other options 
to choose from, and Wilson’s approach did help some individuals who 
were struggling with addiction. But while addiction and the disease mod-
el of addiction was not well understood by scientists and medical profes-
sionals at the time Bill Wilson wrote his Big Book, “advances in science 
and medicine have drawn a much clearer picture of addiction—including 
its causes, correlates and how to treat it—yet we are woefully unprepared 
to apply this evidence to practice.”26 
Moreover, addiction is a disease with significant social repercus-
sions, and many people are unwilling to risk the consequences that might 
result from seeking treatment and revealing the extent of their addic-
tion.27 For those who do choose to seek treatment, they often encounter 
significant barriers to receiving care in a “treatment non-system.”28 Most 
general practitioners are untrained in addiction medicine and are une-
                                                                                                                                      
 22. Id. (“Addiction affects 16 percent of Americans ages 12 and older—40 million people. That 
is more than the number of people with heart disease (27 million), diabetes (26 million) or cancer (19 
million).”). 
 23. Id. at 1. 
 24. Id. at 7. 
 25. Id. at ii (“There are no national standards of care. Patients face a patchwork of treatment 
programs with vastly different approaches; many offer unproven therapies and little medical supervi-
sion. Some promise ‘one time’ fixes; others offer posh residential treatment at astronomical prices with 
little evidence justifying the cost.”). 
 26. Id. 
 27. Id. 
 28. Id. Although many people say they would go to their primary care provider for assistance 
with addiction, “most doctors are uninformed about this disease and rarely are equipped to offer a 
diagnosis, provide treatment or connect patients with appropriate specialty care. Insurance coverage 
varies widely.” Id. Most available services are not individually tailored “and are based primarily on an 
acute care model rather than recognizing the chronic nature of the disease.” Id.; see also Charles Dack-
is & Charles O’Brien, Neurobiology of Addiction: Treatment and Public Policy Ramifications, 8 
NATURE NEUROSCIENCE 1431, 1431 (2005) (“Even patients with access to treatment typically discover 
that its duration is severely limited by insurance company policies . . ., even though addiction is a 
chronic illness requiring sustained aftercare. Imagine limiting treatment duration for diabetes, chronic 
heart failure or hypertension.”). 
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quipped to diagnose or provide treatment for addiction.29 Addiction 
counselors provide the majority of addiction treatment, but most do not 
have medical training and many states do not require them to have any 
type of education.30 As the National Center on Addiction and Substance 
Abuse at Columbia University (“CASA”) notes: “There simply is no 
other disease where appropriate medical treatment is not provided by 
the health care system and where patients instead must turn to a broad 
range of practitioners largely exempt from medical standards.”31 
Addiction has therefore been marginalized “as a social problem ra-
ther than [treated] as a medical condition.”32 Instead of receiving treat-
ment, many individuals with addiction go untreated, and for some of 
them, their first exposure to treatment can come as a result of involve-
ment with the criminal justice system.33 One way individuals enter into 
addiction treatment after they have been arrested or otherwise involved 
in the criminal justice system is through diversion into a “problem-
solving court.” These courts were first conceived of as a way to provide 
addiction treatment to individuals whose involvement with the criminal 
justice system was likely due to an underlying addiction.34 The first drug 
court was established in Florida in 1989, and today there are over 3,000 
drug courts across the country.35 The drug court model has proven popu-
lar, and states have established other specialty courts, including mental-
health courts, tribal courts, reentry courts, DWI courts, juvenile drug 
courts, domestic violence courts, and many others.36 
These problem-solving courts offer would-be defendants “a choice 
of participating in an intensive court-monitored treatment program as an 
alternative to the normal adjudication process.”37 As this Article will ex-
plore, however, much of this required treatment is premised on the 12-
                                                                                                                                      
 29. See CASA REPORT, supra note 21, at 3. 
 30. Id. (“Only six states require a bachelor’s degree and only one state requires a master’s de-
gree.”). 
 31. Id. As the authors note, “[m]uch of what passes for ‘treatment’ of addiction bears little re-
semblance to the treatment of other health conditions [and has not] been subject to rigorous scientific 
study . . . .” Id. at 4. Furthermore, most treatment programs have not incorporated “the existing body 
of evidence demonstrating principles of effective treatment . . . .” Id. 
 32. Id. at 4 (“This profound gap between the science of addiction and current practice related to 
prevention and treatment is a result of decades of marginalizing addiction as a social problem rather 
than treating it as a medical condition.”). 
 33. Id. at 11. 
 34. RYAN S. KING & JILL PASQUARELLA, THE SENTENCING PROJECT, DRUG COURTS: A 
REVIEW OF THE EVIDENCE 1 (2009). 
 35. JUST. POL’Y INST., ADDICTED TO COURTS: HOW A GROWING DEPENDENCE ON DRUG 
COURTS IMPACTS PEOPLE AND COMMUNITIES 2 (Mar. 2011), [hereinafter ADDICTED TO COURTS] 
http://www.justicepolicy.org/uploads/justicepolicy/documents/addicted_to_courts_final.pdf.  
 36. Other problem-solving courts include truancy court, prostitution court, homelessness court, 
and many others. Id. at 18–20; see also WEST HUDDLESTON & DOUGLAS MARLOWE, PAINTING THE 
CURRENT PICTURE: A NATIONAL REPORT ON DRUG COURTS AND OTHER PROBLEM-SOLVING 
COURT PROGRAMS IN THE UNITED STATES 8 (2011) (“The extraordinary success of Adult Drug 
Courts has produced a wide variety of other types of Drug Court programs.”). 
 37. JAMES L. NOLAN, JR., REINVENTING JUSTICE: THE AMERICAN DRUG COURT MOVEMENT 5 
(2001). 
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step treatment model of addiction.38 Such a model is out of step with our 
current understanding of the disease of addiction and corresponding best 
practices for the treatment of this disease. This Article argues that if in-
dividuals are to be compelled by drug courts to seek treatment for addic-
tion, that treatment should be evidence-based and provided by trained 
and qualified medical and mental health professionals. 
Part II of this Article will discuss contemporary scientific under-
standing of the disease of addiction and its diagnosis. Part III will outline 
current treatments for addiction and substance use disorder. This Part 
will first explore evidence-based treatment, including psychosocial and 
pharmacological treatments for addiction. This Part will then examine 
mutual support and 12-step treatment approaches, which comprise the 
majority of addiction treatment available in this country. While these 
types of treatment can be beneficial to individuals suffering from addic-
tion because they are widely available, this Part argue that 12-step, and 
other mutual-support groups, are not evidence-based treatment for ad-
diction and should not be a substitute for scientifically valid treatment 
delivered by qualified professionals. Finally, this Part will examine some 
of the obstacles to evidence-based treatment modalities faced by individ-
uals with addiction. Part IV examines the role of drug courts and other 
specialty courts in the provision of treatment services for addiction in this 
country and argues that these courts should not compel individuals to re-
ceive addiction treatment that is not evidence-based and delivered by 
trained and qualified medical and mental health professionals. Part V 
will conclude. 
II. THE DISEASE OF ADDICTION 
Addiction is a complex brain disease, one that affects multiple parts 
of the brain, “including those involved in reward and motivation, learn-
ing and memory, and inhibitory control over behavior.”39 The continued 
use of substances or compulsive behavior over time can physically alter 
the structure and functioning of the brain, “resulting in changes that per-
sist long after the individual stops taking the drug.”40 Furthermore, the 
                                                                                                                                      
 38. In addition to the clinical reasons outlined in this Article, several circuit courts have held that 
government-mandated attendance at 12-step programs violates the Establishment Clause. See, e.g., 
Kerr v. Ferry, 95 F.3d 472, 474 (7th Cir. 1996) (“We find . . . that the state has impermissibly coerced 
inmates to participate in a religious program.”). For an excellent discussion of the constitutional prob-
lems associated with mandatory 12-step attendance, see Stacey A. Tovino, The House Edge: On Gam-
bling and Professional Discipline, 91 WASH. L. REV. 1253 (2016). 
 39. NAT’L INST. ON DRUG ABUSE (NIDA), PRINCIPLES OF DRUG ADDICTION TREATMENT: A 
RESEARCH BASED GUIDE v (3d ed. 2012) [hereinafter NIDA REPORT]; Dackis & O’Brien, supra note 
28, at 1431 (“[In the United States, the] public . . . views addiction more as a social problem than an 
actual disease, despite scientific evidence supporting a disease concept of addiction based on neuronal 
mechanisms, heritability, treatment responses and a characteristic progressive clinical course.”). 
 40. NIDA REPORT, supra note 39, at 2; see also Alan I. Leshner, Addiction Is a Brain Disease, 
and It Matters, 278 SCIENCE 45, 46 (1997) [hereinafter Leshner I] (“Significant effects of chronic use 
have been identified for many drugs at all levels: molecular, cellular, structural, and functional. The 
addicted brain is distinctly different from the non-addicted brain, as manifested by changes in brain 
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disease has significant behavioral characteristics, and the major hallmark 
of addiction is that it can cause the addicted individual to engage in be-
havior even if that behavior results in unfavorable consequences.41 These 
behavioral components are integral to the diagnosis of substance use dis-
order, a diagnosis that is made using the Diagnostic and Statistical Man-
ual, or DSM-5.42 These findings are all significant because they could, and 
should, radically alter both the treatment of addiction, as well as the 
structure and goals of diversion courts.43 
A. Defining Addiction 
In the past several decades, there has been a huge increase in addic-
tion research that began with animal models and has since expanded to 
include neuroimaging studies of the brains of individuals with addiction.44 
These studies have demonstrated a biological basis for addiction and 
have shown that addiction is a disease that affects the reward centers of 
the brain.45 In turn, these reward centers affect motivation and have 
evolved to control human behavior that is directed towards survival 
goals, even in the presence of danger.46 Addictive drugs and other com-
pulsive behaviors “essentially hijack brain circuits that exert considerable 
dominance over rational thought, leading to progressive loss of control 
over drug intake in the face of medical, interpersonal, occupational and 
legal hazards.”47 
Addictive drugs and other compulsive behaviors produce a feeling 
of euphoria by activating the pleasure centers of the brain, and research 
                                                                                                                                      
metabolic activity, receptor availability, gene expression, and responsiveness to environmental cues.”); 
Alan I. Leshner, Addiction is a Brain Disease, 17 ISSUES IN SCI. & TECH. (2001), (2001) [hereinafter 
Leshner II], http://www.issues.org/17.3/leshner.htm. 
 41. NIDA REPORT, supra note 39. Significantly, there is growing evidence that many behavioral 
addictions share the same essential definition of well-accepted substance addictions, that of a failure to 
control an impulse to engage in the behavior despite harmful or unwanted consequences. In other 
words, it is the brain of the user that dictates the course of the disease of addiction, and not the sub-
stance the individual consumes or the behavior in which she engages. Id. 
 42. See AM. PSYCHIATRIC ASS’N. DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL 
DISORDERS (5th ed. 2013) [hereinafter DSM-5]. 
 43. Finally, it is important to note that addiction often occurs concurrently with or contributes to 
many different medical conditions, including physical conditions like heart disease, as well as mental 
health and behavioral disorders like depression and anxiety. A complete examination of the impact of 
co-occurring disorders is beyond the scope of this article, but for an excellent overview of the issue, see 
Kathleen T. Brady & Rajita Sinha, Co-Occurring Mental and Substance Use Disorders: The Neurobio-
logical Effects of Chronic Stress, 162 AM. J. PSYCHIATRY 1483 (2005) (discussing how comorbidity has 
important implications for therapeutic intervention and prevention programs). 
 44. Dackis & O’Brien, supra note 28, at 1431 (“Much of our knowledge about addiction neuro-
biology is based on decades of animal studies that model the dynamic clinical components of the ill-
ness.”). 
 45. Id. 
 46. Id. (“Given their function, reward centers have evolved the ability to grip attention, domi-
nate motivation and compel behavior directed toward survival goals, even in the presence of danger 
and despite our belief that we are generally rational beings.”). 
 47. Id.; see also Leshner II, supra note 40 (“It is as if drugs have high jacked the brain’s natural 
motivational control circuits, resulting in drug use becoming the sole, or at least the top, motivational 
priority for the individual.”). 
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has shown that different types of substances have the same effect on the 
brain—“opioids, stimulants, alcohol, nicotine, [and] marijuana all in-
crease extracellular dopamine levels” in the brain.48 Once an individual 
experiences this euphoria, she is motivated to experience it again, espe-
cially if that individual possesses certain genetic traits that enhance the 
euphoric effect.49 With continued use, addictive substances disrupt the 
brain’s naturally occurring pleasure centers, and the discontinued use of 
the particular substance can lead to symptoms of withdrawal.50 These un-
pleasant withdrawal feelings create negative reinforcement from the 
brain, which alternates with the positive reinforcement associated with 
the euphoric feelings experienced by the user and “drive the cycle of ad-
diction.”51 As one author notes, this cycle becomes etched in the brain 
and causes “desire and pleasure [to become] impervious to rational 
thought, clashing with deeply engrained cultural values placed on stoi-
cism and self-control.”52 
Furthermore, recent neurobiological research suggests that the ad-
dictive mechanism of substances or behavior lies not with the substance 
or behaviors themselves, but within the brain of the user. In other words, 
contrary to conventional wisdom, we probably do not need to inde-
pendently diagnose and treat individual addictions like alcohol depend-
ence and drug dependence separately because “the addictive disorders 
might not be independent . . . .”53 As one author suggests, “evidence sup-
porting a broader conceptualization of addiction is emerging.”54 Re-
searchers are beginning to view dependence on certain substances or be-
haviors as part of a syndrome, or a “cluster of symptoms and signs relat-
                                                                                                                                      
 48. Dackis & O’Brien, supra note 28, at 1432. 
 49. Id. (“For instance, there is considerable evidence that individuals with a genetic predisposi-
tion toward alcoholism experience more pleasure from this drug because it produces an exaggerated β-
endorphin response.”). But while genetic factors are “estimated to contribute to 40–60% of the varia-
bility in the risk of addiction,” this also includes the interaction of genetic and environmental factors, 
an interaction that has only recently been explored. Nora D. Volkow, What Do We Know About Drug 
Addiction? 162 AM. J. PSYCHIATRY 1401, 1401 (2005). Furthermore, as Leshner explains, the envi-
ronmental or social context in which one initially experiences a substance also play a role in the evolu-
tion of their addiction: “The person who became addicted in the home environment is constantly ex-
posed to the cues conditioned to his or her initial drug use, such as the neighborhood where he or she 
hung out, drug-using buddies, or the lamppost where he or she bought drugs.” Leshner II, supra note 
40. Exposure to these types of environmental cues “automatically triggers craving and can lead rapidly 
to relapses.” Id.  
 50. See Brady & Sinha, supra note 43, at 1486. 
 51. Dackis & O’Brien, supra note 28, at 1432. 
 52. Id. 
 53. Howard J. Shaffer et al., Toward a Syndrome Model of Addiction: Multiple Expressions, 
Common Etiology, 12 HARV. REV. PSYCHIATRY 367, 367 (2004) (“The current view of separate addic-
tions is similar to the view espoused during the early days of AIDS diagnosis, when rare diseases were 
not yet recognized as opportunistic infections of an underlying immune deficiency syndrome.”). In-
deed, some researchers have argued that “major psychiatric syndromes may eventually be understood 
as families of related disorders that are individually distinguished by specific combinations of genetic 
and nongenetic susceptibility factors.” See Steven E. Hyman & Wayne S. Fenton, What Are the Right 
Targets for Psychopharmacology?, 299 SCIENCE 350, 350 (2003). 
 54. Shaffer et al., supra note 53. 
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related to an abnormal underlying condition . . . .”55 What this means is 
that there is a growing recognition of the need to treat addiction more 
generally.56 When treatments become too focused on individual addictive 
substances or behaviors, “they may not be addressing the actual underly-
ing disease of addiction or the possibility of addiction substitution, where 
a patient may replace one form of addiction with another.”57 
As other commentators have noted, however, “the discourse 
around addiction remains contentious and complex.”58 Some suggest that 
the current emphasis on a brain-disease model of addiction is a well-
intentioned attempt to “debunk the moralized argument that addiction is 
a problem for weak-willed people,” but may instead only serve to further 
stigmatize those suffering from addiction.59 Instead, these commentators 
suggest a biological understanding of addiction, one that uses biology to 
explain a condition with social ramifications: “a chronic, relapsing, bi-
opsychosocial disorder that cannot be understood apart from social con-
text—not simply as a brain disease.”60 
As this objection to the brain-disease model suggests, however we 
characterize the disease of addiction, it is still a disease that begins due to 
the voluntary use of a substance and “[m]any people also erroneously 
still believe that drug addiction is simply a failure of will or of strength of 
character.”61 And even if we accept that addiction is a disease of the 
brain, we must still accept that the addicted individual has a role to play 
in both her addiction and in her recovery. “Thus, having this brain dis-
ease does not absolve the addict of responsibility for his or her behavior, 
but it does explain why an addict cannot simply stop using drugs by sheer 
                                                                                                                                      
 55. Id. See generally Kenneth Blum et al., Sex, Drugs, and Rock ‘N’ Roll: Hypothesizing Com-
mon Mesolimbic Activation as a Function of Reward Gene Polymorphisms, 44 J. PSYCHOACTIVE 
DRUGS 38 (2012); Jon Grant et al., Introduction to Behavioral Addictions, 36 AM. J. DRUG & 
ALCOHOL ABUSE 233 (2010). 
 56. CASA REPORT, supra note 21, at 8 (describing a need to treat the “antecedents, manifesta-
tions and consequences of addiction more generally”). 
 57. Id. 
 58. Rachel Hammer et al., Addiction: Current Criticism of the Brain Disease Paradigm, 4 AM. J. 
BIOETHICS NEUROSCIENCE 27, 28 (2013); see also Daniel Z. Buchman et al., Negotiating the Relation-
ship Between Addiction, Ethics, and Brain Science, 1 AM. J. BIOETHICS NEUROSCIENCE 36, 42 (2010) 
(“Neuroethics challenges arise when knowledge exclusively from neuroscience is deemed adequate to 
obtain a full understanding of a mental health disorder as complex as addiction. While the practicali-
ties of a biopsychosocial systems model may allow for a more integrative explanation for addiction, it 
does not explain addiction entirely.”). 
 59. Hammer et al., supra note 58, at 28–30 (describing the concept of “othering” as a way in 
which human groups react to other “groups of people who exhibit unfavorable behavior or character-
istics against the backdrop of cultural norms. Those who believe that diseasing addiction will reduce 
stigma fail to recognize how disease itself has its own stigma; the diseased are often just as set apart as 
‘wretches’ and ‘sinners.’”) (citation omitted). 
 60. Id. at 31 (“We are embodied beings. Biologically, that addiction rests on a neurochemical 
platform is evident and potentially useful. However, it is not necessary to frame addiction as a disease 
to access the benefits from biological addiction research.”); see also Buchman et al., supra note 58, at 
37 (advocating “a biopsychosocial systems model of, and approach to, addiction in which psychological 
and sociological factors complement and are in a dynamic interplay with neurobiological and genetic 
factors”). 
 61. Leshner II, supra note 40. 
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force of will alone.”62 It also suggests the need for a “much more sophisti-
cated approach to dealing with the array of problems surrounding drug 
abuse and addiction in our society.”63 
Furthermore, as one author notes, perhaps it does not matter so 
much how we characterize addiction: “Twenty years of scientific research 
has taught that focusing on this physical versus psychological distinction 
is off the mark and a distraction from the real issues.”64 Instead, what 
matters when we talk about addiction is whether an individual suffers 
from “uncontrollable, compulsive craving, seeking, and use, even in the 
face of negative health and social consequences.”65 This is the true defini-
tion of addiction and the one that has been endorsed by psychologists 
and other medical professionals.66 This author suggests a more straight-
forward definition: “Addiction is a brain disease expressed in the form of 
compulsive behavior. Both developing and recovering from it depend on 
biology, behavior, and social context.”67 
Finally, it is important to note that addiction often occurs concur-
rently with, or contributes to, many different medical conditions, includ-
ing physical conditions like heart disease, as well as mental health and 
behavioral disorders like depression and anxiety.68 In fact, a major risk 
factor for addiction is the presence of mental illness.69 While we can in-
terpret this correlation as either a high incident of addiction in the men-
tally ill or as a high incident of mental illness in individuals with addic-
tions, “both views suggest that there may be common neurobiological 
substrates for substance abuse and mental disorders.”70 Studies have 
found that individuals who suffer from psychiatric disorders are more 
likely to become dependent on nicotine, and individuals who are addict-
ed to multiple substances are the most likely to also suffer from a psychi-
atric disorder.71 While the research supports a strong association between 
                                                                                                                                      
 62. Id. 
 63. Id. 
 64. Id. 
 65. Id. (“Compulsive craving that overwhelms all other motivations is the root cause of the mas-
sive health and social problems associated with drug addiction.”). 
 66. See id. 
 67. Id. 
 68. Brady & Sinha, supra note 43, at 1483 (“The high rate of co-occurrence of substance use dis-
orders and other psychiatric disorders is well established.”) (citation omitted). 
 69. M. Tyler Boden & Rudolph Moos, Dually Diagnosed Patients’ Responses to Substance Use 
Disorder Treatment, 37 J. SUBSTANCE ABUSE TREATMENT 335, 335 (2009) (“The prevalence of psy-
chiatric disorders among individuals with substance use disorders (SUDs) is quite high, with estimates 
ranging from 18% to 70% among those seeking treatment for SUDs.”) (citations omitted). 
 70. Volkow, supra note 49; see also Brady & Sinha, supra note 43, at 1483 (“[E]ven conservative 
estimates suggest a high rate of comorbidity between psychiatric disorders and substance use disor-
ders.”). 
 71. Brady & Sinha, supra note 43, at 1483. Interestingly, certain psychiatric disorders seem to be 
more strongly correlated with substance abuse than others. For example, up to 50% of people with 
schizophrenia are dependent on alcohol or illicit drugs and more than 70% are dependent on nicotine. 
Id. at 1489. In contrast, 32% to 54% of individuals with depression also suffer from drug, alcohol, or 
nicotine abuse, though individuals with major depression “are more likely to develop substance use 
disorders, and individuals with substance use disorders are at greater risk for the development of ma-
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psychiatric disorders and substance-abuse disorders, “the nature of the 
relationship . . . is complex” and “these connections constitute just one 
facet of a complex issue.”72 For that reason, it is important courts and 
policymakers be aware of this complexity because “understanding of co-
occurring disorders will be useful only if there is a treatment system in 
place to implement these findings.”73 
B. Diagnosing Addiction 
Even in the face of this ongoing debate about the definition of ad-
diction, “the majority of the biomedical community now considers addic-
tion, in its essence, to be a brain disease: a condition caused by persistent 
changes in brain structure and function.”74 But whether we characterize 
addiction as a brain disease, or a biopsychosocial disorder, or “some-
where in [the] middle ground,”75 the DSM-5 requires clinicians to diag-
nose addiction based on behavioral criteria, not biological criteria.76 By 
this standard, individuals can be diagnosed with a “substance use disor-
der” on a continuum from mild to severe.77 Unlike its predecessor, the 
new edition of the DSM does not distinguish among substances, and al-
most all substances are diagnosed using the same set of behavioral crite-
ria.78 Moreover, the DSM-5 does not use the word “addiction”; although 
the word “addiction” is often used to describe “severe problems related 
to compulsive and habitual use of substances,” the DSM-5 uses the 
“more neutral term substance use disorder . . . to describe the wide range 
of the disorder, from a mild form to a severe state of chronically relaps-
ing, compulsive drug taking.”79 The DSM-5 chose to eliminate “addic-
                                                                                                                                      
jor depression, compared to the general population.” Id. at 1485 (citation omitted). Similarly, 64% to 
84% of veterans with PTSD met criteria for alcohol abuse. Id. at 1487. 
 72. Id. at 1490. 
 73. Id. 
 74. Leshner II, supra note 40; see also DSM-5, supra note 42, at 483 (“An important characteris-
tic of substance use disorders is an underlying change in brain circuits that may persist beyond detoxi-
fication, particularly in individuals with severe disorders.”). 
 75. Hammer et al., supra note 58, at 2. As one author frankly notes,  
the United States is stuck in its drug abuse metaphors and in polarized arguments about them. 
Everyone has an opinion . . . . People see addiction as either a disease or as a failure of will. None 
of this bumpersticker [sic] analysis moves us forward. The truth is that we will make progress in 
dealing with drug issues only when our national discourse and our strategies are as complex and 
comprehensive as the problem itself. 
Leshner II, supra note 40. 
 76. DSM-5, supra note 42. The new version eliminated the separate diagnoses of substance “de-
pendence” and “abuse” and replaced them with a single diagnosis of “substance use disorder.” Id. at 
484–85. 
 77. Id. at 484 (“Substance use disorders occur in a broad range of severity, from mild to severe, 
with severity based on the number of symptom criteria endorsed.”). 
 78. As the DSM-5 notes, “the diagnosis of a substance use disorder can be applied to all 10 clas-
ses included in this chapter except caffeine. For certain classes some symptoms are less salient, and in a 
few instances not all symptoms apply . . . .” Id. at 483. The ten classes of addictive substances refer-
enced in the DSM include alcohol, caffeine, cannabis, hallucinogens, inhalants, opioids, sedatives, 
stimulants, and tobacco. Id. at 482. 
 79. Id. at 485. 
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tion . . . because of its uncertain definition and its potentially negative 
connotation.”80 
To be diagnosed with Substance Use Disorder, the individual must 
meet two of the eleven criteria listed in the DSM-5.81 If the individual 
meets two or three criteria, this indicates a mild substance use disorder; 
meeting four or five factors indicates a moderate disorder; and meeting 
six or more indicates a severe substance use disorder.82 The eleven crite-
ria in the DSM-5 can be further broken down into four different catego-
ries: impaired control, social impairment, risky use, and physiological ef-
fects.83 Criterion A, Impaired Control (DSM Criterion 1–4), relates to the 
individual’s loss of control over her substance use. This category includes 
situations in which the person takes the substance in larger amounts or 
over a longer period of time than she originally intended; the person tries 
to cut down or regulate her substance use and is unsuccessful; the person 
spends large amounts of time obtaining, using, or recovering from the 
substance; and the person has intense cravings for the substance, espe-
cially in environments where she previously used or obtained the sub-
stance.84 
Criterion B, Social Impairment (DSM Criterion 5–7), includes social 
impairment, which arises when the person’s substance use results in a 
failure to fulfill obligations at work, school, or home; the person contin-
ues use despite social or other interpersonal problems; or the person 
withdraws from important social, work, and recreational activities be-
cause of her substance use.85 Criteria C, Risky Use (DSM Criterion 8–9), 
pertains to risky use of a particular substance, and involves the use of the 
substance in dangerous situations, or continued use of a substance de-
spite knowledge that the substance is likely to affect the person’s physical 
or psychological well-being.86 Finally, Criteria D, Physiological Effects 
(DSM Criterion 10–11), includes pharmacological criteria, and are met 
when the person develops a tolerance to the substance and must use 
greater amounts to achieve the desired effect, and when an individual 
develops withdrawal symptoms upon discontinued use of the substance.87 
                                                                                                                                      
 80. Id. Although the DSM has eliminated the word “addiction,” many clinicians and researchers 
continue to use the term and this Article will use both “addiction” and “substance use disorder” to 
encompass “substance use disorder” as it is defined in the DSM-5. 
 81. These factors essentially combined the traditional criteria under both substance abuse and 
substance dependence. The new DSM also adds drug craving to the list of diagnostic criteria, and elim-
inates “problems with law enforcement,” because of “cultural considerations that make the criteria 
difficult to apply internationally.” See AM. PSYCHIATRIC ASS’N, SUBSTANCE-RELATED AND 
ADDICTION DISORDERS 1 (2013) [hereinafter DSM-5 FACT SHEET], https://psychiatry.org/File% 
20Library/Psychiatrists/Practice/DSM/APA_DSM-5-Substance-Use-Disorder.pdf.  
 82. DSM-5, supra note 42, at 484. 
 83. Id. at 483–84. 
 84. Id. at 483. 
 85. Id. 
 86. Id. (“The key issue in evaluating this criterion is not the existence of the problem, but rather 
the individual’s failure to abstain from using the substance despite the difficulty it is causing.”). 
 87. Id. at 483–84. 
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Furthermore, there is a growing literature examining “behavioral 
addictions,” or nonsubstance addictions, which are “analogous to sub-
stance addiction, but with a behavioral focus other than ingestion of a 
psychoactive substance.”88 Apart from gambling disorder, which the most 
recent version of the DSM has moved to a new section entitled “Non-
Substance-Related Disorders,”89 these types of behaviors are typically 
classified as impulse-control disorders, and include things like kleptoma-
nia and pyromania.90 Other behaviors were considered for inclusion in 
the DSM, including compulsive buying, pathologic skin picking, sexual 
addiction, excessive tanning, computer/video game playing, and Internet 
addiction.91 Of these, only Internet Gaming Disorder found a place in the 
DSM-5 as a condition that should receive further study.92 
And while there is growing evidence that other behavioral addic-
tions like Internet addiction,93 excessive tanning,94 or excessive eating95—
very closely resemble substance addiction, “it is still premature to con-
sider other behavioral addictions as full-fledged independent disor-
ders.”96 Nevertheless, there is growing evidence that many behavioral 
addictions share the same essential definition of well-accepted substance 
addictions, that of a “failure to resist an impulse, drive, or temptation to 
perform an act that is harmful to the person or to others.”97 For that rea-
                                                                                                                                      
 88. Grant et al., supra note 55, at 233. 
 89. The DSM-5 also created a separate section for “Non-Substance-Related Disorders,” which 
includes gambling disorder as its only condition. “Although some behavioral conditions that do not 
involve ingestion of substances have similarities to substance-related disorders, only one disorder—
gambling disorder—has sufficient data to be included in this section.” DSM-5, supra note 42, at 586. 
As the American Psychiatric Association notes, “[t]his new term and its location in the new manual 
reflect research findings that gambling disorder is similar to substance-related disorders in clinical ex-
pression, brain origin, comorbidity, physiology, and treatment.” See DSM-5 FACT SHEET, supra note 
81; see also, Tovino supra note 38. 
 90. Jon E. Grant et al., Impulse Control Disorders: Clinical Characteristics and Pharmacological 
Management, PSYCHIATRIC TIMES (June 1, 2013), http://www.psychiatrictimes.com/impulse-control-
disorders/impulse-control-disorders-clinical-characteristics-and-pharmacological-management. 
 91. Grant et al., supra note 55, at 233. 
 92. Because “existing data are most extensive for pathological gambling,” there was sufficient 
evidence to warrant including it as a behavioral addiction in the DSM-5. Grant et al., supra note 55, at 
238. Mark D. Griffiths, Internet Gaming Disorder vs. Internet Addiction Disorder, PSYCHOLOGY 
TODAY (July 27, 2016), https://www.psychologytoday.com/blog/in-excess/201607/internet-gaming-
disorder-vs-internet-addiction-disorder (“Additional research may eventually lead to evidence that 
Internet gaming disorder has merit as an independent disorder.”). 
 93. See, e.g., Aviv Weinstein & Michel Lejoyeux, Internet Addiction or Excessive Internet Use, 36 
AM. J. DRUG & ALCOHOL ABUSE 277, 277 (2010) (“Problematic Internet use, or addiction, is charac-
terized by excessive or poorly controlled preoccupations, urges or behaviors regarding Internet use 
that lead to impairment or distress.”). 
 94. See, e.g., Carolyn J. Heckman et al., Preliminary Investigation of the Predictors of Tanning 
Dependence, 32 AM. J. HEALTH. BEHAV. 451, 452 (2008) (“Several similarities exist between tanning 
and substance use. They are both prevalent in youth, are often initially perceived as image enhancing, 
and are health-risk behaviors that people participate in despite warnings.”). 
 95. See, e.g., Jeffrey L. Fortuna, The Obesity Epidemic and Food Addiction: Clinical Similarities 
to Drug Dependence, 44 J. PSYCHOACTIVE DRUGS 56, 56 (2012) (“There appear to be several biologi-
cal and psychological similarities between food addiction and drug dependence including craving and 
loss of control.”). 
 96. Grant et al., supra note 55, at 238. 
 97. Id. at 234. 
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son, the “use of repetitive actions, initiated by an impulse that can[not] 
be stopped, causing an individual to escape, numb, soothe, release ten-
sion, lessen anxiety or feel euphoric, may redefine the term addiction to 
include experience and not just substance.”98 This contemporary under-
standing of addiction and its manifestations has led to the corresponding 
development of effective and evidence-based treatment for addiction, as 
well as to the scientific community’s rejection of outmoded forms of ad-
diction treatment. These developments are discussed in the next Part. 
III. TREATMENT FOR ADDICTION 
They tried to make me go to rehab but I said, ‘No, no, no.’99 
As our understanding of the mechanism of addiction grows, so too 
does our knowledge of effective treatments. At the outset, addiction 
must be understood as a chronic illness. In other words, once an individ-
ual is addicted, it is as if she has “crossed a threshold,” past which most 
individuals are not able to turn back.100 Most individuals with addiction 
are never able to return to the occasional use of substances.101 Further-
more, while some addicted individuals are able to abstain from further 
substance abuse with a short duration of treatment, or no treatment, the 
majority will need ongoing treatment, and relapses are common.102 Ongo-
ing treatment is typically necessary, however, to “increase the intervals 
between and diminish the intensity of relapses, until the individual 
achieves abstinence.”103 
Addiction is complex and has a variety of causes and risk factors, 
including physiological, psychological, and environmental factors.104 Ac-
cordingly, any effective clinical treatment will include components that 
attempt to address those various factors and should entail “a multi-
pronged approach . . . that includes a combination of pharmaceutical and 
psychosocial therapies” that are delivered by qualified addiction treat-
ment professionals.105 And while drug treatment therapies for a variety of 
addictive substances and behaviors have been found to be effective in the 
treatment of addiction,106 an extensive body of literature has also found 
that drug therapies combined with various types of behavioral therapies 
                                                                                                                                      
 98. Reef Karim & Priya Chaudhri, Behavioral Addictions: An Overview, 44 J. PSYCHOACTIVE 
DRUGS 5, 5 (2012). 
 99. AMY WINEHOUSE, Rehab, on REHAB (Island Records 2006). 
 100. Leshner II, supra note 40 (“Clinical observation and more formal research studies support 
the view that, once addicted, the individual has moved into a different state of being. It is as if a 
threshold has been crossed. Very few people appear able to successfully return to occasional use after 
having been truly addicted.”). 
 101. Id. 
 102. Id. 
 103. Leshner II, supra note 40.  
 104. CASA REPORT, supra note 21, at 92. 
 105. Id. 
 106. See Leshner I, supra note 40, at 45. 
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is most effective in the treatment of addiction.107 This finding is consistent 
across addictive substances, from opioids,108 to alcohol,109 to cocaine.110 
Notwithstanding our growing understanding of effective treatment 
for addiction, few people who engage in either risky use or abuse of sub-
stances receive adequate, ongoing, evidence-based treatment. If treat-
ment is defined to include all services received in inpatient, residential 
settings (like rehabilitation facilities, hospitals, or mental health facilities) 
and at long-term or short-term outpatient facilities (like doctors’ offices), 
but to exclude mutual-support programs or services received in an emer-
gency room or jail, almost 90% of individuals with addiction receive no 
treatment at all.111 In other words, the majority of treatment that is re-
ceived in this country includes services received in an emergency set-
ting—typically when an individual is detained in an emergency room or 
jail setting—or services received in mutual support and 12-step programs. 
Often, individuals who seek out or are ordered into treatment receive 
“brief, episodic interventions,” which might be part of the explanation 
for high rates of relapse among substance abusers.112 
As this Part will discuss, our contemporary understanding of addic-
tion has led to significant developments in the evidence-based treatment 
of the disease, including psychosocial and pharmacological treatments 
for addiction. Notwithstanding these developments, however, the majori-
ty of addiction treatment in this country continues to be based on a 12-
step orientation and delivered in mutual-support groups by well-meaning 
but untrained individuals. While these types of treatment can be benefi-
cial to individuals suffering from addiction because the treatments are 
widely available, mutual-support groups and other 12-step programs are 
not evidence-based treatment for addiction and should not be a substi-
tute for scientifically valid treatment delivered by qualified professionals. 
                                                                                                                                      
 107. See L. Amato et al., Psychosocial Combined with Agonist Maintenance Treatments Versus 
Agonist Maintenance Treatments Alone for Treatment of Opioid Dependence, 4 COCHRANE 
DATABASE SYSTEMIC REV. 1, 2 (2011); Albert J. Arias et al., Treatment of Co-Occurring Alcohol and 
Other Drug Use Disorders, 31 ALCOHOL RES. & HEALTH 155, 156 (2008); Kathleen Carroll et al., Effi-
cacy of Disulfiram and Cognitive Behavior Therapy in Cocaine-Dependent Outpatients: A Randomized 
Placebo Controlled Trial, 61 ARCHIVES GEN. PSYCHIATRY 264, 271 (2004).           
 108. Amato et al., supra note 107 (“Maintenance treatments with pharmacological agents can 
help to reduce the risks associated with the use of street drugs for drug addicts who are unable to ab-
stain from drug use.”). 
 109. Arias et al., supra note 107 (“In general, an approach that combines behavioral and pharma-
cologic treatments is optimal for most patients. However, recent findings from studies of the pharma-
cotherapy of alcohol dependence have shown that some patients may do well when medication is 
combined with a minimal behavioral approach focusing on medication adherence.”). 
 110. Carroll et al., supra note 107 (“[I]t is important to remember that even the most powerful 
pharmacotherapies for substance use disorders can be rendered ineffective unless delivered with ade-
quate psychosocial treatment and that carefully targeted behavioral therapies can dramatically en-
hance pharmacotherapy compliance and effectiveness.”). 
 111. CASA REPORT, supra note 21, at 131. 
 112. Id. at 7. 
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A. Evidence-Based Treatment and Best Practices 
Alcohol- and substance-use disorders are the realm of medicine. This 
is not the realm of priests.113 
Like treatment for other chronic diseases, “best practices for the ef-
fective treatment and management of addiction must be consistent with 
the scientific evidence of the causes and course of the disease.”114 Best 
practices for addiction treatment first require a comprehensive assess-
ment of the patient, including “a thorough history, physical examination, 
screen for psychiatric illness, and psychosocial evaluation.”115 Following 
this assessment, the patient should be stabilized and receive medical 
management of withdrawal, or detoxification, if necessary, before treat-
ment begins. Next, the patient should receive acute treatment, which 
should be “delivered by qualified health care professionals via evidence-
based pharmaceutical and/or psychosocial addiction treatments, accom-
panied by treatment for co-occurring health conditions.”116 Next, the in-
dividual should receive chronic-disease management to assist with 
maintenance of the progress achieved during the acute treatment phase 
and to help the individual prevent relapse.117 Finally, the patient should 
receive support services, which include wraparound services in the com-
munity like legal, educational, employment, and housing support, as well 
as connection to community-based, mutual-support programs.118 
Best practices also require that treatment and provision of services 
should be by “physicians, nurses, counselors, psychologists, social work-
ers, other health care professionals, and treatment facilities.”119 Profes-
sional treatment is therefore defined as treatment offered by individuals 
“trained within their professional discipline regarding substance use dis-
orders and addiction.”120 Sponsors and other peers in mutual-support 
groups are “not considered to be providers of professional treatment.”121 
The DSM’s description of substance use disorder as a “pattern of 
behaviors”122 that can include a “broad range of severity”123 reflects the 
fact that there is tremendous variation among individuals in how they 
experience and respond to substance use or behavioral compulsions.124 
                                                                                                                                      
 113. Glaser, supra note 11 (citation omitted). 
 114. CASA REPORT, supra note 21, at 9; see also AM. SOC’Y ADDICTION MED., PUBLIC POLICY 
STATEMENT ON TREATMENT FOR ALCOHOL AND OTHER DRUG ADDICTION 2 (2010), [hereinafter 
ASAM REPORT], http://www.asam.org/docs/publicy-policy-statements/1treatment-4-aod-1-10.pdf?sfvr 
sn=0 . 
 115. ASAM REPORT, supra note 114, at 2; see also CASA REPORT, supra note 21, at 9. 
 116. CASA REPORT, supra note 21, at 9; see also ASAM REPORT, supra note 114, at 2. 
 117. CASA REPORT, supra note 21, at 9; see also ASAM REPORT, supra note 114, at 2. 
 118. CASA REPORT, supra note 21, at 9; see also ASAM Report, supra note 114, at 2. 
 119. ASAM Report, supra note 114, at 3. 
 120. Id. at 3–4. 
 121. Id. at 3. 
 122. DSM-5, supra note 42, at 483. 
 123. Id. at 484. 
 124. CASA REPORT, supra note 21, at 7 (“There is tremendous variation in the severity and 
course of the disease of addiction and of its symptoms. Some individuals may experience one episode 
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Notwithstanding these individual differences, however, the disease of 
addiction “manifests as a chronic disease—a persistent or long-lasting ill-
ness—which requires ongoing professional treatment and manage-
ment.”125 Best practice suggests that treatment for substance use disorder 
should be “tailored to the particular stage and severity of the disease, a 
patient’s overall health status, past treatments and any other personal 
characteristics and life circumstances that might affect patient out-
comes.”126 In other words, there is no “one size fits all” cure for addiction 
treatment.127 
In general, however, programs that include both pharmacological 
and behavioral treatments are more effective than either treatment 
alone, and “an approach that combines behavioral and pharmacologic 
treatments is optimal for most patients.”128 The combination of treatment 
modalities is often more successful for several reasons. First, one treat-
ment modality may enhance or increase compliance with the other—
“medication may help patients better tolerate withdrawal symptoms that 
otherwise might have discouraged their participation in psychosocial 
therapy and psychosocial therapy might encourage patients to initiate 
and maintain a course of pharmaceutical therapy.”129 Similarly, because 
every patient will respond to different treatments differently, combining 
therapies increases the chance of success for each patient.130 
To date, the FDA has approved three drugs for treating opioid-use 
disorders, and three drugs for treating alcohol-use disorders.131 For the 
treatment of opioid-use disorder, methadone can be used to prevent 
withdrawal symptoms and reduce cravings by “activating opioid recep-
tors in the brain.”132 Similarly, buprenorphine can reduce or eliminate 
withdrawal and cravings by activating and blocking opioid receptors in 
the brain but without producing the euphoria of heroin or other opi-
oids.133 Buprenorphine can be used alone or in combination with nalox-
                                                                                                                                      
in which their symptoms meet clinical diagnostic criteria for addiction and be non-symptomatic there-
after.”). 
 125. Id.  
 126. Id. at 10. 
 127. Richard A. Rawson et al., Addiction Pharmacotherapy 2000: New Options, New Challenges, 
32 J. PSYCHOACTIVE DRUGS 371, 372 (2011) (“All of this new information and all of the research on 
addiction would be unnecessary if our current treatments resulted in recovery for everyone who en-
tered treatment or attended AA meetings. Unfortunately, our current treatments can’t claim 100% 
success. There are many individuals who try, try and try again, but still can’t get sober.”). 
 128. Arias et al., supra note 107, at 156. 
 129. CASA REPORT, supra note 21, at 104 (citing various studies). 
 130. Id. 
 131. CINDY MANN ET AL., MEDICATION ASSISTED TREATMENT FOR SUBSTANCE USE DISORDERS 
3–4 (2014), http://www.medicaid.gov/federal-policy-guidance/downloads/cib-07-11-2014.pdf; see also 
Hannah K. Knudsen et al., Barriers to the Implementation of Medication-Assisted Treatment for Sub-
stance Use Disorders: The Importance of Funding Policies and Medical Infrastructure, 34 EVALUATION 
PROGRAM PLAN. 375, 375 (2011) [hereinafter Knudsen 2011]. For an excellent summary of research 
on pharmacotherapies for specific substance use disorders, see Arias et al., supra note 107, at 157 tbl.2. 
 132. MANN ET AL., supra note 131, at 3 (“[Methadone has a long history of use in treatment of 
opioid dependence in adults, and is available in specially licensed methadone treatment programs.”).  
 133. Id. at 3–4. 
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one, which causes withdrawal symptoms if the individual uses opioids.134 
Naloxone can also be used to prevent overdose; “[t]he medication binds 
to opioid receptors and can rapidly reverse or block the effects of other 
opioids . . . [and] very quickly restore the normal respiration” of a person 
who has slowed or stopped breathing as a result of an overdose of opi-
oids.135 Finally, naltrexone is used to prevent relapse following detoxifica-
tion from opioids.136 It blocks the brain’s opioid receptors and therefore 
prevents any euphoria the person might experience following use of opi-
oids.137 
In addition to medications available for opioid abuse, three medica-
tions have received FDA approval for the treatment of alcohol abuse. 
The first, acamprosate, reduces symptoms of alcohol withdrawal includ-
ing insomnia, anxiety, restlessness, and unease.138 In contrast, disulfiram 
inhibits an enzyme that is necessary to metabolize alcohol, and causes an 
unpleasant reaction, including flushing and nausea, if alcohol is con-
sumed.139 Finally, naltrexone blocks the euphoric effects of alcohol the 
same way it does in the case of the treatment of opioid abuse.140 
Pharmacological therapies are most effective when used in conjunc-
tion with evidence-based psychosocial therapies, many of which have 
been proven effective in the treatment of substance use.141 Cognitive be-
havioral therapy teaches individuals with addiction techniques to recog-
nize and avoid places or situations that trigger their craving for drugs or 
alcohol, as well as strategies for minimizing those triggers.142 Some of the 
most common behavioral therapies used in the treatment of addiction in-
clude motivational interviewing and contingency management.143 In mo-
tivational interviewing, the therapist engages in structured conversations 
with patients that help the patients increase motivation to overcome sub-
stance use.144 In contingency management therapy, therapists or counse-
                                                                                                                                      
 134. Id. at 4. 
 135. Id. 
 136. Id. 
 137. Id. at 4 (“[Naltrexonel] can be taken orally in tablets or as a once-monthly injection given in 
a doctor’s office.”). 
 138. See Arias et al., supra note 107, at 159 tbl.3. 
 139. Id. 
 140. See id. 
 141. Id. at 156. For patients with alcohol dependence, studies have found that some patients re-
spond well to medication assisted treatment combined with “a minimal behavioral approach focusing 
on medication adherence.” Id. For individuals with drug dependence, “behavioral therapies are often 
considered primary and medications secondary,” except in the case of patients with opioid addictions, 
who often benefit from long-term opioid agonist maintenance therapy. Id. 
 142. R. Kathryn McHugh et al., Cognitive-Behavioral Therapy for Substance Use Disorders, 33 
PSYCHIATRIC CLINICS N. AM. 511, 512 (2010). 
 143. Arias et al., supra note 107, at 156 tbl.1 (noting that other behavioral therapies include Brief 
Intervention, Contingency Management, Community Reinforcement, Motivational Enhancement 
Therapy, and 12-Step Facilitation). 
 144. McHugh et al., supra note 142, at 512 (“Motivational interviewing . . . is an approach based 
on targeting ambivalence toward behavior change relative to drug and alcohol use . . . .”). 
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lors give patients “tangible incentives to encourage patients to stay off 
drugs [or alcohol],” including cash rewards or increased privileges.145 
While there have been great strides in addiction treatment modali-
ties, and the evidence supports the use of both pharmacological and psy-
chosocial treatments for most individuals, the majority of addiction 
treatment in this country continues to be provided much as it was when 
William Wilson wrote his Big Book almost 100 years ago. That is, most 
addiction treatment is provided in mutual-support groups by individuals 
who often have little education or training about addiction, apart from a 
history of addiction themselves.146 While this type of support is admirable 
and can be a helpful supplement to evidence-based treatment delivered 
by qualified professionals, it should not continue to compromise the pri-
mary treatment model available to individuals with addiction, particular-
ly when those individuals are compelled by drug or other specialty courts 
to receive that treatment. 
B. The Dominant Treatment Model—Mutual Support 
Alcoholics Anonymous should remain forever non-professional.147 
12-step groups like Alcoholics Anonymous and Narcotics Anony-
mous (“NA”) are “nonprofessional organization[s] that [are] operated by 
recovering . . . peers, [are] free of charge to members, and may be at-
tended indefinitely.”148 The term “mutual support” is often used to de-
scribe these types of organizations “to reflect the fact that group mem-
bers give and receive advice, encouragement, and support.”149 These 
groups use a philosophy of addiction recovery that emphasizes the ac-
ceptance that recovery is a lifelong process; that addiction is a disease 
that can be managed but not eliminated, and that true recovery means 
                                                                                                                                      
 145. Id. at 512–13 (“Contingency management approaches are grounded in operant learning theo-
ry and involve the administration of a non-drug reinforce (e.g., vouchers for goods) following demon-
stration of abstinence from substances.”). 
 146. ELEANOR SULLIVAN & MICHAEL FLEMING, U.S. DEP’T HEALTH & HUMAN SERVS., A 
GUIDE TO SUBSTANCE ABUSE SERVICES FOR PRIMARY CARE CLINICIANS 66 (1997), https://www.ncbi. 
nlm.nih.gov/books/NBK64827/pdf/Bookshelf_NBK64827.pdf. 
 147. The Twelve Traditions of Alcoholics Anonymous, ALCOHOLICS ANONYMOUS (2014), http:// 
www.aa.org/assets/en_US/smf-122_en.pdf. 
 148. AM. SOC’Y ADDICTION MED. & RESEARCH SOC’Y ON ALCOHOLISM, 16 RECENT 
DEVELOPMENTS IN ALCOHOLISM 149–50 (Marc Galanter ed. 2003) (ebook) (“Although ‘Alcoholics 
Anonymous’ and ‘12-step’ treatment are sometimes used interchangeably, they differ in a number of 
important respects.”); see also M. Ferri et al., Alcoholics Anonymous and Other 12-Step Programmes 
for Alcohol Dependence (Review), COCHRANE DATABASE SYSTEMATIC REV., Mar. 2006 at 1, 2 (2006) 
(defining AA as a “self-help group, organised through an international organization of recovering al-
coholics, that offers emotional support and a model of abstinence for people recovering from alcohol 
dependence using a 12-step approach” and noting that “[a]s well as AA, there are also alternative in-
terventions based on 12-step type programmes, some self-help and some professionally-led”). 
 149. Keith Humphreys et al., Self-Help Organizations for Alcohol and Drug Problems: Toward 
Evidence-Based Practice and Policy, 26 J. SUBSTANCE ABUSE TREATMENT, 151, 151–52 (2004). 
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“enhancing individual maturity and spiritual growth, minimizing self-
centeredness, and providing help to other addicted individuals.”150 
Many professional alcohol treatment programs also use the 12-step 
model as a basis for treatment. And while AA and “twelve-step treat-
ment” are often used interchangeably, it is important to note that formal 
12-step treatment approaches are distinct from AA, NA, and other self-
help or mutual-support groups. Unlike AA, “12-step alcoholism treat-
ment programs are typically licensed/accredited, have paid professional 
staff, charge fees, and offer services for a defined period.”151 These pro-
fessional organizations often use the 12-steps and AA literature to guide 
therapy approaches, and typically employ recovering counselors and en-
courage or require participants to attend AA meetings.152 Different 12-
step treatment programs incorporate the 12-step principles to a larger ex-
tent than others. For instance, some “have no purpose other than to en-
courage 12-step self-help group meeting attendance, whereas others 
make 12-step ideas a strong focus of ongoing treatment,” or “deliver 12-
step influenced treatment services in the context of a larger medical, pro-
fessionalized setting.”153 
Self-help and mutual-support groups like AA and NA can be tre-
mendously helpful to individuals with substance use disorders, and “lon-
gitudinal studies associate AA and NA participation with greater likeli-
hood of abstinence, improved social functioning, and greater self-
efficacy.”154 Furthermore, participation in self-help groups can help con-
nect participants with community-based services, and provide long-term 
social support to members. At the same time, “[n]o experimental studies 
unequivocally demonstrated the effectiveness of AA . . . approaches for 
reducing alcohol dependence or problems,” and self-help and other mu-
tual-support groups are not, and should not, be a substitution for evi-
dence-based treatment.155 Instead, AA and other mutual-support pro-
grams are “best viewed as a form of continuing care rather than as a 
substitute for acute treatment services.”156 Indeed, the research suggests 
that it is not the content of the programs or their procedures that are as-
sociated with positive outcomes, but that these programs are free, long-
                                                                                                                                      
 150. Id. at 152; see also NAT’L QUALITY FORUM, EVIDENCE-BASED TREATMENT PRACTICES FOR 
SUBSTANCE USE DISORDERS C-15 (2005) [hereinafter NATIONAL QUALITY FORUM]. 
 151. RESEARCH ON ALCOHOLISM TREATMENT, supra note 148, at 150. 
 152. Id. 
 153. Id. at 151. 
 154. NATIONAL QUALITY FORUM, supra note 150, at C-15. 
 155. Ferri et al., supra note 148, at 2, 11 (“12-step and AA programmes for alcohol problems are 
promoted worldwide. Yet experimental studies have on the whole failed to demonstrate their effec-
tiveness in reducing alcohol dependence or drinking problems when compared to other interven-
tions.”).  
 156. NATIONAL QUALITY FORUM, supra note 150, at C-15. 
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term, and easily accessible and are supportive of long-term recovery, 
which is a key element of any chronic-disease management approach.157 
In this country, addiction treatment services are most often provid-
ed through community-based programs established before the disease 
model of addiction became prominent, and these programs often include 
significant components of 12-step or other mutual-support philoso-
phies.158 An average of five million people ages twelve and older attend 
an alcohol or other drug-use, mutual-support group each year.159 Because 
AA and other mutual-support programs do not keep records of member-
ship and intentionally lack an internal organizational structure, it can be 
difficult to pinpoint exact numbers,160 but several estimates suggest that 
the majority of private and public treatment providers use some variation 
of a 12-step model.161 A 2004 study of privately162 and publicly163 funded 
treatment providers found that 75% of private treatment providers and 
60% of public treatment providers “indicated that the 12-step model best 
characterized their program.”164 Even among those centers that described 
themselves as offering something other than 12-step programming, al-
most half reported programing that incorporated the 12-step model in 
                                                                                                                                      
 157. Ferri et al., supra note 148, at 11 (“In general, the available research seems to be concentrat-
ed on prognostic factors associated with assumedly successful treatments rather than on the effective-
ness of treatments in themselves.”).  
 158. CASA REPORT, supra note 21, at 109–10; NAT’L TREATMENT CENTER STUDY, SUMMARY 
REPORT (No. 8) 22 (2004) [hereinafter NTCS PRIVATE STUDY]. As Glaser notes,  
As the rehab industry began expanding in the 1970s, its profit motives dovetailed nicely with 
AA’s view that counseling could be delivered by people who had themselves struggled with ad-
diction, rather than by highly trained (and highly paid) doctors and mental-health professionals. 
No other area of medicine or counseling makes such allowances. 
Glaser, supra note 11. 
 159. CASA REPORT, supra note 21, at 110. 
 160. NATIONAL QUALITY FORUM, supra note 150, at C-15 (“The anonymous nature of these pro-
grams is an inherent barrier to studying the effect of this type of support.”). 
 161. NATIONAL TREATMENT CENTER STUDY, SUMMARY REPORT 21 (Sep. 2004) [hereinafter 
NTCS PUBLIC STUDY]; NTCS PRIVATE STUDY, supra note 158, at 22; Lea Winerman, Breaking Free 
from Addiction, 44 MONITOR PSYCHOL. 30, 31 (2013), http://www.apa.org/monitor/2013/06/ 
addiction.aspx (“[P]rograms might involve wilderness camping, abusive tactics labeled ‘tough love,’ 
and, most commonly, Alcoholics Anonymous and Narcotics Anonymous, peer-support models that 
have helped many addicts but failed many others.”); Glaser, supra note 11.  
 162. NTCS PRIVATE STUDY, supra note 158, at 22. This study included 401 privately funded 
treatment centers in forty-five states and the District of Columbia. Each center in the study “received 
less than 50% of their annual operating revenues from government grants and/or contracts” and the 
“average center in this sample received only 10% of its revenues from [state or Federal] sources.” Id. 
at 3, 5. 
 163. NTCS PUBLIC STUDY, supra note 161, at 21. This study included 362 publicly funded treat-
ment centers. Each center in the study received “more than 50% of their annual operating revenues 
from government grants or contracts (including block grant funds),” and the “average center partici-
pating in this study sample received 86% of its annual revenues from such sources.” Id. at 3.  
 164. Id. at 21 (“Centers evidenced significant regional variations in 12-step orientation, with those 
in the Midwest (73.0%) and South (64.0%) significantly more likely than those in the West (47.0%) to 
base their treatment models on a 12-step approach.”); see also NTCS PRIVATE STUDY, supra note 158, 
at 22 (“Centers evidenced significant regional variations in 12-step orientation, with those in the South 
(87.0%) significantly more likely than those in the Northeast (68.0%) and the West (47.0%) to base 
their treatment models on a 12-step approach.”). 
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conjunction with other treatment modalities.165 Furthermore, in 66% of 
private centers and 64% of public centers, “attendance at 12-step meet-
ings during the course of treatment is a ‘requirement,’”166 and 66.5% of 
private centers and 59.7% of public centers hold 12-step meetings on 
site.167 
Although mutual-support programs can be tremendously helpful 
and easily accessible means of support for individuals with addiction, 
they “are not evidence-based treatments for the disease [of addiction].”168 
It seems, however, that many people often conflate mutual-support pro-
grams with other evidence-based forms of treatment, and many are simp-
ly not aware that evidence-based treatment exists.169 For example, while 
the American public “appears to be supportive of assuring that individu-
als with addiction receive effective addiction treatment, public views 
about what constitutes addiction treatment do not comport with the sci-
ence.”170 In CASA’s study, more than 60% of respondents spontaneously 
defined “treatment” as AA, NA, or some other type of mutual-support 
program.171 Because mutual-support programs are often the most visible 
form of treatment available in many communities, it appears that many 
people believe they are an independent form of treatment, when instead 
these programs are “highly useful systems of support that should accom-
pany or follow evidence-based clinical treatment.”172 
For most illnesses or diseases, treatment is based on best practices 
and administered by highly trained medical professionals. In contrast, the 
disease of addiction is often treated on the fringes of mainstream medi-
cine, in mutual-support programs by individuals with little or no medical 
training, and treatment is rarely supervised by trained medical profes-
sionals.173 Physicians, nurses, and other medical professionals typically 
serve a peripheral role and are consulted only when necessary.174 Fur-
                                                                                                                                      
 165. “Other centers tended to emphasize cognitive behavioral therapies, or an eclectic mix of ap-
proaches which generally incorporate[d] 12-step as one component.” NTCS PUBLIC STUDY, supra 
note 161, at 21; NTCS PRIVATE STUDY, supra note 158, at 22. 
 166. NTCS PUBLIC STUDY, supra note 161, at 21; see also NTCS PRIVATE STUDY, supra note 158, 
at 22. 
 167. NTCS PUBLIC STUDY, supra note 161, at 21; see also NTCS PRIVATE STUDY, supra note 158, 
at 22. See generally Timothy Edwards, The Theory and Practice of Compulsory Drug Treatment in the 
Criminal Justice System: The Wisconsin Experiment, 2000 WIS. L. REV. 283 (2000).  
 168. CASA REPORT, supra note 21, at 10. 
 169. Id. at 208 (“The overwhelming salience and considerable evidence—although largely anec-
dotal—of the benefits of mutual-support programs like Alcoholics Anonymous (AA), for example, 
have led many people to conflate such support services with actual addiction treatment . . . .”). 
 170. Id. at 10. Supportive does not necessarily mean optimistic, however. As one author notes, 
“[i]ndeed, a significant proportion of Americans feel that ‘nothing works’ for a dependent individual.” 
A. Thomas McLellan & Kathleen Meyers, Contemporary Addiction Treatment: A Review of Systems 
Problems for Adults and Adolescents, 56 BIOLOGICAL PSYCHIATRY 764, 764 (2004). 
 171. CASA REPORT, supra note 21, at 10. 
 172. Id. at 208. 
 173. Id. at 212.  
 174. Id. ( “Physicians and other medical professionals typically are absent from or on the periph-
ery of the treatment process, occasionally being called in to provide a prescription or medically moni-
tor a detoxification protocol.”). Even physicians, who “make up the smallest share of providers of ad-
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thermore, most addiction treatment providers do not see this structure as 
problematic.175 When asked who was best suited to provided addiction 
treatment services, almost 75% of CASA respondents said substance-
abuse counselors and fewer than 2% said physicians.176 Fewer than 15% 
of respondents indicated that a medical degree is a “very important” 
qualification for treatment providers, and approximately 25% thought 
that a master’s degree or a bachelor’s degree was very important.177 What 
the majority of respondents did think was important, however, was “per-
sonal experience with addiction.”178 
Finally, and despite evidence that addiction is best understood as a 
syndrome and not specific to one underlying substance or behavior, most 
addiction treatment tends to focus on the individual substances or behav-
iors themselves. For example, even among mutual-support programs, 
“addicted” individuals are typically segregated into Alcoholics Anony-
mous (“AA”), Narcotics Anonymous (“NA”), and Gamblers Anony-
mous (“GA”), to name a few. And while evidence exists supporting the 
efficacy of nonspecific pharmacological and psychological treatments for 
the disease of addiction, many in the treatment community have been 
slow to embrace these techniques, continuing to instead focus on AA’s 
original 12-step model as it has been applied to individual substances or 
behaviors.179 
C. A Neglected Disease: Barriers to Evidence-Based Treatment 
“There is no other disease that affects so many people, has such far-
reaching consequences and for which there is such a broad range of ef-
fective interventions and treatments that is as neglected as the disease of 
addiction.”180 
There are a variety of obstacles to effective and lasting addiction 
treatment. In 2013, 22.7 million adults in the United States needed 
treatment for drug or alcohol addiction or abuse, but only 2.5 million re-
ceived treatment. This means that 20.2 million adults—or 7.7% of the en-
tire United States population—needed treatment for an addiction but 
did not receive it. 181 Many of the people who did not receive treatment 
                                                                                                                                      
diction treatment services, receive little education or training in addiction science, prevention and 
treatment.” Id. at 3. 
 175. Id. at 213. 
 176. Id. 
 177. Id. 
 178. Id. at 213–14 (61.4% of program directors and 76.3% of staff providers felt that personal ex-
perience with addiction was important). 
 179. Shaffer et al., supra note 53, at 372 (“This discrepancy between theory and practice might 
inadvertently contribute to less than optimal treatment outcomes, given that conventional wisdom 
discourages clinicians from paying sufficient attention to the underlying core of addictive behaviors.”). 
 180. CASA REPORT, supra note 21, at 2. 
 181. CTR. FOR BEHAVIORAL HEALTH STATISTICS & QUALITY, U.S. DEP’T. OF HEALTH & 
HUMAN SERVS., RESULTS FROM THE 2013 NATIONAL SURVEY ON DRUG USE AND HEALTH: 
SUMMARY OF NATIONAL FINDINGS 93 (2014) [hereinafter DHHS REPORT]. A person is considered to 
need treatment for substance use disorder “if he or she met the DSM-IV diagnostic criteria for alcohol 
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did not feel they needed it,182 which is the classic problem of “denial.”183 
For others, “there is well-known stigma associated with alcohol and drug 
abuse, leading those with the condition to avoid formal treatment be-
cause of concern about disclosure of information to employers, friends, 
and families.”184 But for people who both need and want treatment, and 
for those who are compelled by courts to receive it, “there is an addition-
al complicating factor—the national treatment delivery system.”185 Much 
of what we know about the effective treatment of addiction has not been 
incorporated into the majority of treatment settings, and the treatment 
that is provided is often delivered by individuals without education or 
training in the mechanisms of addiction or evidence-based treatment. 
Much of what we have learned about appropriate and effective evi-
dence-based treatments for substance use disorder has not made it into 
practice, and many individuals who are in treatment could be helped by 
these research developments. This phenomenon is not unique to addic-
tion. Indeed, “timely realization of the benefits of expensive medical re-
search is an international concern attracting considerable policy effort 
around ‘translation.’”186 In other words, it can be difficult to translate re-
search into practice. Many researchers have estimated this “lag” between 
research and practice to be approximately seventeen years.187 Further-
more, relevant medical research can take even longer to reach lawmakers 
and judges.188 When this effect is combined with the high cost of some 
medications, the unavailability of qualified practitioners to prescribe 
pharmacological treatments, and a general distrust of medication in the 
                                                                                                                                      
or illicit drug dependence or abuse in the past 12 months or if he or she received specialty treatment 
for alcohol use or illicit drug use in the past 12 months.” Id. at 92 (citation omitted). 
 182. See id. at 94. (“In 2013, among the 20.2 million persons aged 12 or older who were classified 
as needing substance use treatment but not receiving treatment at a specialty facility in the past year, 
908,000 persons (4.5 percent) reported that they perceived a need for treatment for their illicit drug or 
alcohol use problem.”) (citation omitted). 
 183. See McLellan & Meyers, supra note 170, at 764. 
 184. Id.; see also Dackis & O’Brien, supra note 28, at 1431 (“Pejorative views toward addictive 
individuals also exist and contribute to policies that would be simply unacceptable if applied to ‘real’ 
medical disorders.”). 
 185. McLellan & Meyers, supra note 170, at 764. 
 186. Zoë Slote Morris et al., The Answer is 17 Years, What is the Question: Understanding Time 
Lags in Translational Research, 104 J. ROYAL SOC’Y MED. 510, 510 (2011) (citing various studies).  
 187. Lawrence W. Green, Diffusion Theory and Knowledge Dissemination, Utilization, and Inte-
gration in Public Health, 30 ANN. REV. PUB. HEALTH 151, 155 (2009) (describing a “17-year odyssey” 
by which knowledge is transferred from research to practice); John M. Westfall et al., Practice-Based 
Research—“Blue Highways” on the NIH Roadmap, 297 JAMA 403, 403 (2007) (“It takes an estimated 
average of 17 years for only 14% of new scientific discoveries to enter day-to-day clinical practice.”); 
cf. Gail Yokote & Robert A. Utterback, Time Lapses in Information Dissemination: Research Labora-
tory to Physician’s Office, 62 BULL. MED. LIBR. ASS’N. 251, 253 (1974) (“Thus, it took from 1958 until 
1970 before the concept of using L-Dopa to treat Parkinsonism became accepted and established.”). 
 188. See generally Harlan Matusow et al., Medication Assisted Treatment in US Drug Courts: Re-
sults from a Nationwide Survey of Availability, Barriers and Attitudes, 44 J. SUBSTANCE ABUSE 
TREATMENT 473 (2013). 
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treatment of addiction, it is no surprise that fewer than 25% of drug 
courts employ pharmacological-based treatments.189 
A variety of state and federal agencies have attempted to improve 
and prioritize substance abuse treatment, specifically the use of pharma-
cological treatments in conjunction with other evidence-based psychoso-
cial therapies.190 For example, the Network for the Improvement of Ad-
diction Treatment (“NIATx”) is a “community of addiction treatment 
programs that apply a simplified set of process improvement strategies to 
the delivery . . . of addiction treatment services.”191 NIATx’s work is sup-
ported by awards from the Robert Wood Johnson Foundation and the 
Substance Abuse and Mental Health Services Administration, and works 
to help community-based treatment facilities deliver appropriate and ev-
idence-based addiction treatment and to increase the implementation of 
pharmacotherapies.192 Similarly, the National Institute on Drug Abuse 
(“NIDA”) is working to increase the adoption of evidence-based treat-
ment through the introduction of clinical trials in real-world treatment 
settings.193 Furthermore, there have been significant private and public 
investments in research meant to develop additional pharmacotherapies 
for the treatment of substance use disorders, including drugs that can be 
used to treat cocaine addiction and to treat other addictions in special 
populations, like pregnant women.194 
Notwithstanding the availability and efficacy of various addiction 
treatment modalities, however, many addiction treatment providers do 
not use evidence-based treatment practices and instead “address addic-
tion in ways that have not been evaluated or proven effective.”195 This is 
partly due to the training and qualifications of the majority of treatment 
providers, many of whom do not have extensive education about effec-
                                                                                                                                      
 189. URBAN INST. JUSTICE POLICY CTR., 2 THE MULTI-SITE ADULT DRUG COURT EVALUATION 
51 (Nov. 2011) [hereinafter MULTI-SITE ADULT DRUG COURT EVALUATION] (23% of drug courts 
provide “pharmacological interventions”); see also COMM. ON CMTY.-BASED DRUG TREATMENT, 
INST. OF MED., BRIDGING THE GAP BETWEEN PRACTICE AND RESEARCH 29 (Sara Lamb et al., eds., 
1998) (“There are important gaps between the knowledge . . . from research, everyday practice in 
community-based drug abuse treatment programs, and governmental policies about drug abuse treat-
ment at the local, state, and national levels . . . . These groups make too little use of one another’s 
knowledge base.”). 
 190. Knudsen 2011, supra note 131, at 375 (“Improving the quality of substance abuse treatment 
through the implementation of evidence-based treatment practices . . . has increasingly been the focus 
of federal and state agencies as well as private foundations.”); Dennis McCarty et al., Improving Care 
for the Treatment of Alcohol and Drug Disorders, 36 J. BEHAV. HEALTH SERVS. & RES. 52, 52 (2009) 
[hereinafter McCarty Improving Care] (“Reports from the Institute of Medicine’s Committee on the 
Quality of Health Care in America challenge the American health care system to prioritize patient 
needs, implement evidence-based decision making, and reduce inefficiency and errors in medical 
care.”). 
 191. McCarty Improving Care, supra note 191, at 53. 
 192. See id.; see also Knudsen 2011, supra note 131, at 375. 
 193. Knudsen 2011, supra note 131, at 375. 
 194. Frank Vocci & Walter Ling, Medications Development: Successes and Challenges, 108 
PHARMACOLOGY & THERAPEUTICS 94, 94–95 (2005) (“The National Institute on Drug Abuse funds a 
broad portfolio of research on drugs of abuse and the causes and treatment of addictive disorders.”). 
 195. CASA REPORT, supra note 21, at 215. 
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tive evidence-based treatment for addiction but have extensive interac-
tion with patients at most treatment facilities.196 As one author notes, 
“counselors are quite important in all aspects of clients’ experience in 
treatment.”197 Among treatment counselors, those who have more exten-
sive training in evidence-based treatment, as well as those who work in 
facilities where evidence-based treatments are used, tend to perceive 
these treatments as more acceptable for treating addiction.198 Further-
more, counselors with more education are more supportive of evidence-
based treatments than those with less education.199 Finally, support staff, 
who often have more patient contact than counselors or other personnel, 
“showed little enthusiasm for evidence-based practices” and were “more 
likely to support intervention techniques that employ confrontation and 
coercion—techniques that contradict evidence-based practice.”200 
Although addiction affects nearly 10% of Americans,201 there is a 
shortage of addiction treatment providers in the United States.202 Moreo-
ver, most treatment providers have little or no medical training.203 Addi-
tionally, unlike most medical care in this country, which is heavily regu-
lated and delivered by educated and trained medical professionals, 
                                                                                                                                      
 196. Id. (“Most also are not trained in the scientific method or clinical research, further impeding 
their ability to integrate clinical research findings into treatment practice.”); see also MaryLouise E. 
Kerwin et al., Comparative Analysis of State Requirements for the Training of Substance Abuse and 
Mental Health Counselors, 30 J. SUBSTANCE ABUSE TREATMENT 173, 179 (2006) (“Most drug and al-
cohol counselors have not had the necessary coursework to facilitate a deep understanding of research 
articles, and results from at least one study suggest that drug and alcohol counselors would 
agree . . . .”). 
 197. Thomas D’Aunno, The Role of Organization and Management in Substance Abuse Treat-
ment: Review and Roadmap, 31 J. SUBSTANCE ABUSE TREATMENT 221, 230 (2006). 
 198. CASA REPORT, supra note 21, at 216; see also Dennis McCarty et al., Direct Care Workers in 
the National Drug Abuse Treatment Clinical Trials Network: Characteristics, Opinions, and Beliefs, 58 
PSYCHIATRIC SERVS. 181, 188 (2007) [hereinafter McCarty Direct Care] (examining support for the 
use of medication to treat alcohol and drug problems and finding only “modest levels of support”). As 
the authors note, many treatment providers are not aware of the latest research regarding pharmaco-
logical treatments for addiction and “the field of drug abuse treatment has much work to do before the 
use of medication becomes a routine part of treatment plans. The good news is that opinions were not 
strongly negative, and education and training appear to promote more positive opinions.” Id. at 189. 
 199. CASA REPORT, supra note 21, at 216; see also Lena Lundgren et al., Addiction Treatment 
Provider Attitudes on Staff Capacity and Evidence-Based Clinical Training: Results from a National 
Study, 20 AM. J. ON ADDICTIONS 271, 283 (2011) (“Staff with higher levels of education and who rated 
their organization higher with respect to the organization’s promoting of organizational change were 
more likely to show higher levels of preference for training based on scientific evidence.”) (internal 
reference omitted); McCarty Direct Care, supra note 198, at 188 (“[A]cceptance of new practices was 
found to be strongly correlated with education.”).  
 200. CASA REPORT, supra note 21, at 216; see also McCarty Direct Care, supra note 198, at 185 
(finding that individuals in support roles were consistently more likely to believe “that drug use indi-
cates a lack of treatment readiness, that confrontation should be used more often, and that noncom-
pliant patients should be discharged”). 
 201. In 2013, “an estimated 21.6 million persons aged 12 or older (8.2%) were classified with sub-
stance dependence or abuse in the past year based on criteria specified in the” fourth edition of the 
Diagnostic and Statistical Manual of Mental Disorders, (DSM-IV). DHHS REPORT, supra note 181, at 
7. 
 202. CASA REPORT, supra note 21, at 176. (“According to data collected from 1996 to 1997, there 
are 134,000 full-time staff and 201,000 total staff (including part-time and contract staff) working in 
addiction treatment.”). 
 203. Id. 
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addiction treatment is most often provided by addiction counselors.204 
While these treatment providers are often highly motivated and dedicat-
ed to their patients, their only qualification is often a history of personal 
addiction. Many have only a bachelor’s degree, and some have no educa-
tion past high school.205 Furthermore, there are very few standards gov-
erning the providers of addiction treatment, and “standards vary by pay-
er and by state.”206 Addiction counselors comprise the majority of the 
addiction workforce in the United States, yet many states require only a 
high school diploma and some practical experience, which typically in-
volves a 12-step model.207 
Furthermore, training for addiction treatment providers has evolved 
separately from other mental health professionals, “probably because 
health care professionals often were not interested in treating addiction 
problems.”208 For this reason, many recovering addicts themselves took 
on the role of treatment provider, using expertise gained through experi-
ence and based largely on 12-step principles.209 Unlike mental health pro-
fessionals, for whom there was a mainstream educational path, many ad-
diction treatment providers are self-trained or have undergone an 
apprenticeship model of education.210 Moreover, state requirements for 
substance abuse counselors are much less stringent than those for mental 
health counselors. While 98% of states require a Masters degree to quali-
fy as a mental health counselor, 45% do not require a college degree to 
qualify as a substance abuse counselor.211 Similarly, while 86% of states 
require a credential to qualify as a mental health counselor, only half re-
quire the same credential to qualify as a substance abuse counselor.212 
Some researchers have also argued that part of the disconnect be-
tween addiction treatment and other branches of mainstream medicine is 
due to the societal stigma of addiction and that this stigma “contribute[s] 
to policies that would be simply unacceptable if applied to ‘real’ medical 
disorders.”213 Individuals with addiction are often not treated as patients, 
but instead blamed or criminalized for their behavior.214 Moreover, addic-
tion treatment, particularly pharmacological treatment, is seen as unnec-
                                                                                                                                      
 204. Id. 
 205. Id.; McLellan & Meyers, supra note 170, at 767. 
 206. CASA REPORT, supra note 21, at 178. 
 207. Kerwin et al., supra note 196, at 175. 
 208. Id. at 173 (internal citation omitted). 
 209. Id. 
 210. Id. at 178 ( “[A]ddiction counseling can best be categorized as having an apprentice model of 
training in which the majority of knowledge, skills, and abilities needed to practice are acquired on the 
job under the supervision of a mentor or a supervisor”). But as Kerwin also notes, “In the past several 
decades, however, marketplace trends caused primarily by managed care have resulted in a reported 
increase in the didactic and formal training of addiction counselors.” Id. at 173–74 (internal citation 
omitted). 
 211. Id. at 178. 
 212. Id. 
 213. Dackis & O’Brien, supra note 28, at 1431 (“Stigma and misconception create formidable ob-
stacles to a more enlightened public policy toward addictive illness.”). 
 214. Id. 
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essary because the individual should “just say no,” or is seen as ineffec-
tive because it simply substitutes one addiction for another.215 In turn, 
these attitudes are embraced by “an uneducated yet strongly opinionated 
public [that] does not understand the technical field of addiction neuro-
biology and is more likely to conceptualize addiction as a character flaw . 
. . than a brain disease.”216 
This divergence of substance abuse treatment education from that 
of mainstream medicine, in general, and mental health education, in par-
ticular, has had implications for the practice of addiction treatment and 
the dissemination of research findings to practice. The treatment provid-
er workforce is often untrained in evidence-based treatments and has 
high rates of turnover.217 As a result, many treatment providers are simp-
ly “not equipped to provide consistent evidence-based treatment.218 Tra-
ditionally, new research findings are disseminated to practice through re-
porting in peer-reviewed journals, which professionals are typically 
taught to read in graduate school.219 Without this formal training, many 
addiction treatment providers “may have greater difficulty deciphering 
and appreciating these research findings.”220 Moreover, many addiction 
treatment providers may simply be unaware of new types of evidence-
based approaches to addiction treatment. 
Because addiction treatment has existed at the fringes of main-
stream medicine, providers of addiction treatment are often hesitant to 
use evidence-based pharmaceutical treatments.221 This underutilization of 
drug therapies to treat addiction is often seen in smaller, unaccredited 
                                                                                                                                      
 215. Id. 
 216. Id. 
 217. CASA REPORT, supra note 21, at 213 (“The treatment provider workforce, although fre-
quently highly dedicated, is composed primarily of certified alcoholism and substance abuse counse-
lors []—a profession for which a college degree typically is not required and in which counselors re-
ceive limited on-the-job training in evidence-based practices”) (footnote omitted); see also McLellan 
& Meyers, supra note 170, at 768. As the authors note, the organizational and personnel “infrastruc-
tures of many treatment programs are fragile and unstable.” Most treatment programs “did not have a 
full-time physician or nurse, and very few programs had any social workers or psychologists. There are 
also disturbing levels of staff turnover at all levels. From the counselors to the directors, more than 
half had not been in their jobs for even 1 year.” Id. (internal citations omitted). 
 218. CASA REPORT, supra note 21, at 213. These evidence-based treatments include “administer-
ing and monitoring medication protocols, implementing complex psychosocial interventions, address-
ing co-occurring health conditions or responding to medical problems that may arise among individu-
als undergoing addiction and treatment.” Id.; see also Todd A. Olmstead et al., Counselor Training in 
Several Evidence-Based Psychosocial Addiction Treatments in Private US Substance Abuse Treatment 
Centers, 120 DRUG & ALCOHOL DEPENDENCE 149, 149 (2012) (“[M]ost addiction counselors in the 
US are said to enter the field unprepared to [implement evidence-based practices and] the vast majori-
ty of [evidence-based] training typically occurs on the job.”) (internal citations omitted). 
 219. Kerwin et al., supra note 196, at 179.  
 220. Id. 
 221. CASA REPORT, supra note 21, at 206 (“[P]roviders of addiction treatment vastly underuti-
lize evidence-based pharmaceutical therapies.”); see also Knudsen 2011, supra note 131, at 376 (“Re-
cent health services research has documented the limited adoption of MAT by SUD treatment organi-
zations, particularly in programs heavily reliant on governmental sources of funding . . . .”). 
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treatment programs, programs that are publically funded,222 programs 
that are not affiliated with or located in a hospital,223 or programs that 
have few trained medical professionals on staff.224 As the CASA report 
notes, “among privately- and publicly-funded treatment programs, ap-
proximately half have adopted at least one pharmaceutical treatment for 
addiction.”225 This means, of course, that half of the treatment programs 
in the United States have not adopted any type of pharmaceutical treat-
ments for their patients, despite the fact that these medications are FDA 
approved and widely available. 
Part of the reluctance to utilize available pharmaceutical therapies 
in addition to psychosocial treatment for addiction is a lack of qualified 
providers on staff with the ability to prescribe such treatments,226 or a 
lack of certainty among physicians as to the appropriate medication or 
dosage to prescribe.227 One recent study of administrators of publically 
funded treatment centers throughout the United States found that when 
asked about reasons for their reluctance to use pharmaceutical treat-
ments, most respondents cited the lack of available medical staff quali-
fied to prescribe available medications and state regulations prohibiting 
the prescription of certain medications.228 Although various state and 
                                                                                                                                      
 222. Hannah K. Knudsen et al, Facilitating Factors and Barriers to the Use of Medications in Pub-
licly Funded Addiction Treatment Organizations, 4 J. ADDICTION MED. 99, 99 (2010) [hereinafter 
Knudsen 2010] (“Previous research has shown that publicly funded treatment organizations have 
lagged behind their privately funded counterparts in the adoption of FDA-approved medications for 
the treatment of addiction.”). 
 223. Knudsen 2011, supra note 131, at 379 (“[P]rograms in healthcare settings employed signifi-
cantly more physicians and nurses on staff, which were both associated with medication adoption.”). 
 224. CASA REPORT, supra note 21, at 176; see also Knudsen 2010, supra note 222, at 105 (“With-
out increases in the employment of physicians, nurses, and other medical personnel, there are likely to 
be ceiling effects on the percentage of organizations that can offer medication-assisted treatments.”). 
 225. CASA REPORT, supra note 21, at 206; see also Knudsen 2011, supra note 131, at 377–78 
(finding that among publicly funded treatment programs, “37.0% of centers had adopted at least one 
medication for the treatment of [substance use disorders]”). 
 226. CASA REPORT, supra note 21, at 206 (“Thirty-eight percent of publicly-funded programs do 
not even have access to a prescribing physician, nor do 23 percent of privately-funded programs.”); see 
also Knudsen 2010, supra note 222, at 100 (“[T]he availability of medical personnel, such as physicians 
and nurses, is necessary to support the implementation of medications, yet access to these personnel is 
highly variable across treatment organizations.”). 
 227. CASA REPORT, supra note 21, at 206–07. As the CASA report notes, even physicians may 
underuse pharmacological treatments for addiction “due in part to insufficient evidence regarding op-
timal dosages of certain pharmaceutical therapies, durations of use, how to combine the use of medica-
tions with counseling and the generalizability of research-based efficacy findings to different patient 
populations.” Id.; see also Knudsen 2011, supra note 131, at 376 (describing cultural barriers to the use 
of pharmacological treatments including “staff resistance to the use of medication-assisted treatment 
(MAT), a lack of perceived effectiveness of MAT, and lack of knowledge about how to implement 
MAT within their treatment setting”). 
 228. Knudsen 2011, supra note 131, at 375. The study conducted face-to-face interviews of 318 
administrators of publicly funded treatment centers and included a representative sample of publicly 
funded addiction treatment centers in the US. Other barriers, like “counselor resistance to MAT, per-
ceptions of clinical ineffectiveness, and lack of information about medications, were less frequently 
endorsed by program administrators as important reasons for non-adoption.” Id. at 377. In a follow-up 
study, Knudsen again found that these types of intra-organizational barriers were “not critical barriers 
to adoption,” and instead that a major barrier continued to be “limited access to physicians and other 
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federal agencies have begun devoting resources to disseminating infor-
mation about evidence-based treatments, including pharmacological 
treatments,229 treatment providers may not be aware of this information. 
Moreover, the availability of reimbursement for certain types of medica-
tion-assisted treatment may affect treatment decisions.230 And finally, 
pharmaceutical companies may devote fewer resources to marketing 
available pharmaceutical treatment options to treatment providers.231 
Another reason for the underuse of pharmacological treatment may 
be a perceived incompatibility with abstinence-based treatment ap-
proaches, including 12-step and other mutual-support programs.232 In-
deed, “one of the key predictors of the underutilization of pharmaceuti-
cal treatments is adherence of treatment providers to a strong 12-step 
ideology for addiction treatment.”233 Many treatment providers are for-
mer addicts themselves, and mutual-support programs are often orga-
nized and facilitated by former addicts. In fact, the main prerequisite for 
leadership in many mutual-support programs is a history of addiction and 
a successful recovery.234 These individuals may be resistant to embrace or 
recommend pharmacological therapies to individuals in treatment pro-
grams. One author describes this resistance as a “pharmacophobia”: 
Beyond this “pharmacophobia”—based upon the “medicines are 
bad” rationale—is the much more deeply rooted and strongly held 
belief that recovery has one formula and one pathway and that any 
modification to that approach is simply wrong, if not unethical. For 
individuals with this belief system, scientific evidence is irrelevant. 
                                                                                                                                      
medical personnel who can support the implementation of medication assisted treatments.” Knudsen 
2010, supra note 222, at 106. 
 229. Knudsen 2011, supra note 131, at 375. 
 230. Knudsen 2010, supra note 222, at 106 (“[N]on-Medicaid public funding (e.g. federal block 
grant, state contracts, and criminal justice contracts) was a barrier to the adoption of addiction treat-
ment medications.”); see also Harold A. Pollack & Thomas D’Aunno, Dosage Patterns in Methadone 
Treatment: Results from a National Survey, 1988–2005, 43 HEALTH SERVS. RESEARCH 2143, 2160 
(2008) (“[M]anaged care stringency is associated with lower methadone doses. Unit staff may be reluc-
tant to provide high methadone doses to patients covered by managed care contracts simply because 
such a higher-dose course of treatment requires more time, and managed care shortens treatment du-
ration.”). 
 231. Knudsen 2010, supra note 222, at 106 (“[C]ontact with pharmaceutical representatives was 
positively associated with the adoption of addiction pharmacotherapies, even after controlling for a 
variety of other organizational characteristics.”). Knudsen also notes, however, that “the average 
treatment center had little contact with pharmaceutical company representatives.” Id. at 107. 
 232. CASA REPORT, supra note 21, at 206. 
 233. Id.; see also Pollack & D’Aunno, supra note 230, at 2160 (noting the connection “between 
managerial attitudes and methadone dose levels”). As the authors note, “managers who support an 
abstinence orientation . . . are more likely to be in units that also provide low doses. After three dec-
ades of experience, basic differences and ambivalence about the proper goals of treatment continue to 
influence clinical practice, underscoring the contested role of methadone treatment for opiate disor-
ders.” Id. But see Knudsen 2010, supra note 222, at 108 (“Taken together, these findings point to prob-
lems in the capacity to adopt medications based on current resources rather than a lack of willingness 
or cultural opposition to adoption. Infrastructure development, particularly in terms of medical staff-
ing, and the alignment of funding policies may yield important gains in medication adoption.”). 
 234. CASA REPORT, supra note 21, at 208. (“Mutual support programs are facilitated by mem-
bers whose main credential is that they themselves have experienced an addictive disorder and have 
learned to manage it.”); see also Rawson et al., supra note 127, at 372. 
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They believe they have the “truth” about recovery and don’t want 
to be bothered with other points of view. To some degree, this posi-
tion is based upon personal experience of recovery and honestly 
held beliefs. However, there are other less idealistic issues that can 
contribute to this position. For many recovering paraprofessional 
counselors, their counseling “trump card” is that their personal ex-
perience is exemplary of how recovery works.235 
One study of addiction treatment counselors asked about the coun-
selor’s attitudes towards six different types of evidence-based treatment, 
including drug therapies and psychosocial therapies.236 The researchers 
consistently found that “greater adherence to a 12-step orientation was 
related to lower perceived acceptability” of the evidence-based treat-
ments and that counselors who had at least a master’s level education 
“reported significantly higher perceived acceptability.”237 A different 
study found that treatment facilities with greater 12-step orientation “are 
less likely to have medical and social services available for clients.”238 
When new treatments are developed, especially those that rely on one 
drug to achieve abstinence from another, “the ‘do what I did’ model may 
not fit as well” and “these changes may be seen as a real threat.”239 
There is, therefore, a large gap between what we know about addic-
tion treatment and the education and training received by addiction 
treatment providers. Notwithstanding our understanding of addiction as 
a brain disease, the treatment of addiction exists almost entirely without 
regulation “within a fragmented system of care with inconsistent regula-
tory oversight.”240 
Most medical professionals are not appropriately trained about ad-
diction, and most addiction treatment providers are not medical profes-
sionals and “are not equipped with the knowledge, skills or credentials 
necessary to provide the full range of evidence-based services.”241 This 
disconnect between our understanding of addiction and available addic-
tion treatment has a wide-reaching impact for individuals who attempt to 
receive medical care for addiction in this country, as well as for those in-
                                                                                                                                      
 235. Rawson, supra note 127, at 372. 
 236. INST. FOR BEHAV. RES., CTR. FOR RES. ON BEHAV. HEALTH & HUM. SERVS. DELIVERY. 
NATIONAL TREATMENT CENTER STUDY SUMMARY REPORT NO. ELEVEN 6 (2006) [hereinafter NTCS 
STUDY 2006]. These included buprenorphine, methadone, naltrexone, disulfiram, motivational en-
hancement therapy (MET), and voucher-based motivational incentives. 
 237. Id. at 7. 
 238. D’Aunno, supra note 197, at 224. 
 239. Rawson et al., supra note 127, at 372. As Rawson notes, 
The blanket opposition to medication of any form for treating substance abuse disorders has deep 
and very tangled roots. Many recovering individuals learned in their recoveries that doctors and 
their prescription pads were evil purveyors of pharmacologic lies and temptations. . . . Tales of 
these inappropriate treatment experiences are common among many of the ‘old timers’ at 12-
Step meetings. 
Id. 
 240. CASA REPORT, supra note 21, at 176.  
 241. Id. at 175. Furthermore, most treatment facilities are not adequately monitored or regulated 
and are therefore not held accountable for providing evidence-based treatment to patients. Id. at 176. 
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dividuals who are compelled by a drug court to receive that treatment. 
The next Part will address the treatment received by individuals who are 
ordered into treatment as a condition of participation in drug court, and 
makes recommendations for reform that could improve both treatment 
outcomes for drug court participants as well as the ultimate success of 
drug courts in helping individuals with substance use disorder. 
IV. THE USE & ABUSE OF 12-STEP PROGRAMS IN DRUG COURTS 
Drug Courts embraced science like no other criminal justice pro-
gram. They endorsed best practices and evidence-based practices.242 
Diversion—or “problem solving”—courts were first conceived as a 
way to “accommodate offenders with specific needs and problems that 
were not or could not be adequately addressed in traditional courts”243 
and have proliferated throughout the United States over the last several 
decades. In 1989, the first drug court was established in Miami-Dade 
County, Florida.244 This special court was conceived of as a way to pro-
vide addiction treatment to individuals whose involvement with the crim-
inal justice system was likely due to an underlying addiction.245 The drug 
court model drew heavily on therapeutic goals, and received “almost uni-
formly positive media coverage and overwhelming public support at both 
the national and local levels.246 In addition to these therapeutic goals, 
however, drugs courts were developed in response to the large numbers 
of drug cases clogging criminal court dockets.247 Instead of prosecuting 
individuals for crimes they committed as a result of a drug or alcohol ad-
diction, it was reasoned that, instead, there should be “a choice of partic-
ipating in an intensive court-monitored treatment program as an alterna-
tive to the normal adjudication process.”248 
                                                                                                                                      
 242. DOUGLAS B. MARLOWE, NAT’L ASS’N OF DRUG COURT PROF’LS, RESEARCH UPDATE ON 
ADULT DRUG COURTS 1 (2010). 
 243. OFFICE OF JUSTICE PROGRAMS. CTR. FOR PROGRAM EVALUATION & PERFORMANCE 
MEASUREMENT, WHAT ARE PROBLEM SOLVING COURTS?, http://web.archive.org/web/20150814044 
601/http://comingtogetherkalamazoo.org/images/Problem-Solving%20Courts%20Handout.pdf (last 
visited May 31, 2017). 
 244. KING & PASQUARELLA, supra note 34; see also NOLAN, supra note 37, at 39 (“In response to 
the growing number of felony drug cases in Miami, Associate Chief Judge Herbert Klein . . . was 
commissioned to study the problem and offer an alternative approach. Klein’s proposal led to the ini-
tiation of America’s first drug court—a judicially supervised treatment program for drug abusing of-
fenders.”). 
 245. KING & PASQUARELLA, supra note 34. 
 246. NOLAN, supra note 37, at 5 (“Judges celebrate the drug court as an exciting movement, a 
new way of service, even a revolution in American Jurisprudence.”); Michelle Edgely, Why Do Mental 
Health Courts Work? A Confluence of Treatment, Support & Adroit Judicial Supervision, 37 INT’L J. 
LAW & PSYCHIATRY 572, 575 (2014) (“Problem-solving courts implement therapeutic jurisprudence, 
so an even more fundamental purpose of status hearings is to provide an opportunity for the judge to 
establish a therapeutic alliance with the participant.”); NOLAN, supra note 37, at 5 (“Judges celebrate 
the drug court as an exciting movement, a new way of service, even a revolution in American Juris-
prudence.”). 
 247. NOLAN, supra note 37, at 5.  
 248. Id. 
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Drug courts have proven popular, and by 2008 more than 55,000 
people entered drug court each year.249 Due to the success of the drug 
court model, many jurisdictions began creating other problem-solving 
courts, including mental health courts, tribal courts, reentry courts, DWI 
courts, juvenile drug courts, domestic violence courts, and many others.250 
Today, jurisdictions throughout the United States run almost 3,000 drug 
treatment courts and more than 1,000 other problem-solving courts, most 
of which are based on the original drug court model.251 To “support and 
provide leadership to this burgeoning judicial development,” some early 
adopting judges organized the National Association of Drug Court Pro-
fessionals (“NADCP”) in 1994.252 At its 2015 meeting, the NADCP wel-
comed “over 5,000 treatment court professionals from across the globe 
[to its] 21st Annual Training Conference in Washington, DC.”253 
Although these courts vary tremendously, we can identify some 
common characteristics, and the following elements seem to be common 
to all drug diversion courts: 
                                                                                                                                      
 249. AVINASH SINGH BHATI ET AL., JUSTICE POLICY CTR., THE URBAN INST., TO TREAT OR NOT 
TO TREAT: EVIDENCE ON THE PROSPECTS OF EXPANDING TREATMENT TO DRUG-INVOLVED 
OFFENDERS, at xi–xii (2008); see also NOLAN, supra note 37, at 43 (noting that the drug court model 
has spread to other countries, including Canada, Australia, and England). 
 250. ADDICTED TO COURTS, supra note 35, at 18–20. Other problem-solving courts include truan-
cy court, prostitution court, homelessness court, and many others. Id. See also HUDDLESTON & 
MARLOWE, supra note 36 (“The extraordinary success of Adult Drug Courts has produced a wide va-
riety of other types of Drug Court programs.”) These include: 
• Family Dependency Treatment Courts for alcohol and other drug-involved parents in civil 
child abuse or neglect proceedings; 
• Juvenile Drug Courts for alcohol and other drug-involved adolescents charged with delinquen-
cy offenses; 
• DWI Courts for repeat and/or high Blood Alcohol Content (BAC) offenders charged with 
driving under the influence (DUI) or driving while impaired (DWI); 
• Reentry Drug Courts for alcohol and other drug-involved parolees or inmates conditionally re-
leased from custody; Campus Drug Courts for alcohol and other drug-involved college stu-
dents facing expulsion; 
• Campus Drug Courts for alcohol and other drug-involved college students facing expolusion; 
• Tribal Healing to Wellness Courts, which apply traditional Native-American communal prac-
tices to alcohol and other drug-involved tribal law offenders; 
• Federal Reentry/Drug Courts for federal alcohol and other drug involved offenders released 
from federal custody on supervised release; 
• Veterans Treatment Courts for our military veterans (and occasional active duty members) 
who are before the court due to addiction and/or mental illness. 
Id. 
 251. See ADDICTED TO COURTS, supra note 35, at 2; see also HUDDLESTON & MARLOWE, supra 
note 36, at 1 (“As of December 31, 2009, there were a total of 3,648 Drug Courts and other types of 
Problem-Solving Courts in the United States.”). Of these, approximately 2,459 were drug courts and 
the remainder were other specialty courts. Id. 
 252. NOLAN, supra note 37, at 39. 
 253. Record Numbers Attend NADC 21st Annual Training Conference, NAT’L ASS’N OF DRUG 
COURT PROF’LS, http://www.nadcp.org/learn/2015-annual-training-conference (last visited May 30, 
2017). 
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(1) intervention is immediate; (2) the adjudication process is non-
adversarial in nature; (3) the judge takes a hands-on approach to 
the defendant’s treatment program; (4) the treatment program con-
tains clearly defined rules and structured goals for the participants; 
and (5) the concept of the [drug-court] team—that is judge, prose-
cutor, defense counsel, treatment provider, and corrections person-
nel—is important. The needs, problems, and resources of the local 
community dictate the methods and means of the various working 
DTCs, but the goal remains consistent—drug treatment for addict-
ed drug offenders instead of incarceration and/or probation.254 
In this model, the judge approaches each case as the leader of a team 
that includes prosecutors, probation officers, defense attorneys, and so-
cial workers. The team creates a treatment plan that defendants must 
agree to. Defendants participate in a variety of treatments, and while this 
varies considerably by court, these typically include “individual and 
group counseling sessions, and Alcoholics Anonymous (AA) and Nar-
cotics Anonymous (NA) 12-step groups.”255 Drug court participants are 
typically required to submit to regular urinalysis and to check in regular-
ly—typically every two, four, or six weeks—with the judge. Participation 
in drug court is intended to last approximately one year, but can last 
much longer.256 
Drug court is premised on the importance of early intervention and 
personal interaction with the judge.257 The judge speaks to each partici-
pant from the bench and engages them with questions about their pro-
gress and other personal matters. When participants are compliant, the 
regular status hearings are positive and supportive—“judges offer praise, 
applause, and prizes,” and graduation from the program is “celebrated 
with cake, speeches, graduation certificates, individual testimonies by 
graduates, and visits from politicians and other local dignitaries.”258 Clap-
ping is quite common when an individual is “moving up” in the program. 
When a participant is noncompliant because of a failed urinalysis test, 
absence from required counseling or 12-step programs, or a variety of 
                                                                                                                                      
 254. For an excellent overview of the history of drug courts and the similarities and differences 
among various courts, see NOLAN, supra note 37, at ch. 2. 
 255. Id. at 40. 
 256. See, e.g., 430: Very Tough Love, THIS AM. LIFE (Mar. 25, 2011), http://www.thisamericanlife. 
org/radio-archives/episode/430/very-tough-loveo. This describes the story of Lindsey Dills, a 17-year-
old girl who forged two checks from her parents’ bank account, “one for $40 and one for $60,” and was 
a participant in drug court for almost six years. This time period included “14 months behind bars, and 
then . . . another five years after that—six months of it in Arrendale State Prison, the other four and a 
half on probation.” Id.  
 257. Edgely, supra note 246, at 575 (“The primary site for the exercise of judicial problem-solving 
techniques is during regular status hearings. These are designed to monitor the participant’s attend-
ance at treatment appointments and compliance with the conditions of the program.”). The role of the 
attorneys in drug court is also different than in a typical court proceeding as the relationship between 
the prosecutor and the defense attorney is not an adversarial one. NOLAN, supra note 37, at 40 (“In 
many drug courts the lawyers do not even show up for the regular drug court sessions, and even when 
they do, it is often difficult to determine just which persons in the courtroom are attorneys.”). 
 258. NOLAN, supra note 37, at 40. (“Among the small incentives judges might hand out for good 
performance are T-shirts, key chains, donuts, pens, mugs, colored star stickers, and candy.”). 
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other infractions, the penalties can be harsh.259 Sanctions vary but can in-
clude “increased participation in 12-step groups, community service, one 
or two days sitting in the jury box during drug court sessions, or short 
stints in the county jail.”260 
Drug courts and other specialty courts use a variety of methods to 
identify potential participants, with referrals often coming from arresting 
officers, jail personnel, or even family.261 Typically, the treatment team 
will discuss eligibility as a group, and the judge will make the final deci-
sion about eligibility.262 Because these courts are meant to divert individ-
uals out of the criminal justice system, public safety is a primary concern, 
and most courts limit eligibility based on the defendant’s previous crimi-
nal record, as well as the current charges against the defendant.263 In a 
2011 study of all American drug courts, for example, 94.3% of courts 
admitted defendants with felony drug possession charges, but only 47.3% 
admitted those with felony drug sale charges.264 Similarly, most courts will 
accept defendants with felony property offense charges (86.9%) or felo-
ny prostitution charges (71.4%), but few will accept a defendant who is 
charged with a violent crime, including felony domestic violence (20.1%) 
or misdemeanor violence (16.3%).265 Many courts explicitly exclude indi-
viduals charged with crimes against other people or against children.266 
While participating in any diversion court is voluntary, there is sig-
nificant variation in the timing of entry into the court and the disposition 
of the defendant’s criminal charges. In some courts, selected participants 
enter the program before they have entered a plea.267 In other courts, the 
defendant enters a plea and is then assigned to the diversion program;268 
if the defendant successfully completes the program the charges are dis-
missed.269 Finally, in other courts, the defendant is not assigned to the di-
version program until after the conviction; “in these courts, the program 
is essentially, if not actually, a condition of probation.”270 Finally, some 
courts use a combination of these various procedures, depending on the 
underlying charge and the defendant’s criminal history.271 
                                                                                                                                      
 259. Edgely, supra note 246, at 576 (“Of course, it is judges who wield this powerful potential mo-
tivating force. Participants in MHCs have told researchers that they needed the threat of imprison-
ment or some lessening of sentence severity to coalesce their motivation.”). 
 260. NOLAN, supra note 37, at 40. As Nolan details, these short jail stints are “what Judge Stanley 
Goldstein in Dade County euphemistically calls ‘motivational jail.’” Id. 
 261. Id. at 40–41. 
 262. Edgely, supra note 246, at 575. 
 263. NOLAN, supra note 37, at 41. 
 264. MULTI-SITE ADULT DRUG COURT EVALUATION, supra note 189, at 26. 
 265. Id. 
 266. Id. 
 267. NOLAN, supra note 37, at 41. 
 268. Id. 
 269. Id. 
 270. Id. 
 271. Id. 
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While some have called diversion courts a “revolution in criminal 
justice,”272 drug and other specialty courts are not without their critics.273 
Many argue that drug courts discriminate against people of color274 and 
do not accept the individuals who would benefit most from participation 
in the court.275 Others simply point out that while a diversion program 
may be preferable to incarceration for an individual whose crime was 
motivated by a substance abuse disorder, we are still using a “justice sys-
tem approach to a public health issue.”276 Finally, one author describes 
drug court as a kind of theatre, where “carefully written scripts and well-
choreographed performances are used to communicate a particular im-
age of the program to garner public support and encourage others to join 
the movement.”277 
In addition to these criticisms, drug courts and other diversion 
courts “need to be evidence-based” and provide appropriate and effec-
tive treatment and services to participants.278 Yet most specialty courts 
are limited to the treatment providers that are available within their 
communities, and they “often do not have direct control over the quality 
and content of the treatments.”279 In the absence of community providers 
that employ evidence-based pharmacological and psychosocial addiction 
treatment, some commentators have raised “broader policy questions 
about the creation of courts as a gateway into treatment in the absence of 
existing—or the simultaneous creation of—effective community-based 
services.”280 
                                                                                                                                      
 272. See, e.g., id. at 185 (“What we are doing here is no less than a complete revolution in juris-
prudence.”) (quoting Judge Hora). 
 273. See Morris B. Hoffman, The Drug Court Scandal, 78 N.C. L. Rev. 1437 (2000); For an excel-
lent overview of some of the common objections to the drug court model, see ADDICTED TO COURTS, 
supra note 35. 
 274. ADDICTED TO COURTS, supra note 35, at 21. (“Since people of color are more likely to have a 
felony conviction on their record at the time of an arrest related to drug abuse, they are more likely to 
be excluded from consideration for drug court participation.”). 
 275. Id. (“Drug courts that receive federal discretionary grants are required to focus on people 
accused of nonviolent offenses and those without a violent record. Yet research shows that drug courts 
have the greatest benefit for people who have more prior felony convictions and have previously failed 
other dispositions.”). 
 276. See Hoffman, supra note 273, at 1477. (“[When drug courts simultaneously treat] drug use as 
a crime and as a disease [] without coming to grips with the inherent contradictions of those two ap-
proaches, drug courts are not satisfying either the legitimate and compassionate interests of the treat-
ment community or the legitimate and rational interests of the law enforcement community.”). 
 277. NOLAN, supra note 37, at 61. In describing drug court conferences, which have been held 
annually since 1993, Nolan describes “heavily scripted and staged events (where actual Hollywood 
actors with histories of alcohol or substance abuse, such as Martin Sheen, Charlie Sheen, and James 
Caan, have made cameo appearances),” and where drug court professionals have the opportunity to 
“strategize with each other and educate those new to the scene about how best to present the program 
to sometimes skeptical audiences for the purpose of garnering public support and financial resources 
to further the movement.” Id. at 62. 
 278. See Edgely, supra note 246, at 578. 
 279. Mary Ann Campbell et al., Multidimensional Evaluation of a Mental Health Court: Adher-
ence to the Risk-Need-Responsivity Model, 39 LAW HUM. BEHAV. 489, 500 (2015). 
 280. Roger A. Boothroyd et al., Clinical Outcomes of Defendants in Mental Health Court, 56 
PSYCHIATRIC SERVS. 829, 833–34 (2005).  
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A recent national survey of adult drug courts found that, while 98% 
of courts reported that at least some participants were addicted to opi-
oids upon entering the drug court program, two-thirds of these courts did 
not provide medication-assisted treatment to individuals who were using 
illegal opioids at the time they began drug court.281 This study concluded 
that while drug courts were “originally conceived as a more treatment-
based and less punitive approach to substance abuse than incarceration,” 
the procedures and policies in place in many of these courts did not re-
flect current understandings of evidence-based pharmacological treat-
ment for drug abuse.282 In response to open-ended questions in the sur-
vey, some respondents reported concern about participants substituting 
“one high for another” and a resulting “new addiction.”283 Other cited 
barriers included court policies against medication assisted treatment and 
treatment provider policies against medication assisted treatment.284 So 
while “copious medical and scientific research has established that for 
many opioid-addicted people, the need for prolonged, sometimes life-
time medication assisted treatment is necessary to prevent relapse to il-
licit opioid use,” many drug courts continue to limit the availability of 
these pharmacological treatments to participants.285 
According to the Multi-Site Adult Drug Court Evaluation, only 
23% of drug courts provide pharmacological interventions to partici-
pants.286 And while the National Association of Drug Court Professionals 
recently released a resolution noting that “[d]rug court professionals 
have an affirmative obligation to learn about current research findings 
related to the safety and efficacy of [medication assisted treatment] for 
addiction,” and should “not impose blanket prohibitions against the use 
of [medication assisted treatment] for their participants,”287 it is still the 
case that 12-step groups like AA and NA are the most commonly ac-
cessed treatment for individuals in the country with a substance use dis-
order.288 
Drug courts and other specialty courts also help explain the large 
number of referrals of individuals into mutual-support groups and addic-
tion treatment. By some accounts, the criminal justice system accounts 
                                                                                                                                      
 281. Matusow, et al. supra note 188, at 476. The number is even smaller for special populations 
like pregnant women; only one in four courts allow medication assisted treatment for this group. Id.  
 282. Id. at 478.  
 283. Id.  
 284. Id.  
 285. Id. at 479 (“Improved education efforts directed at both drug court personnel and policy 
makers may help dispel some doubts about these evidence-based treatment approaches and the medi-
cal consensus on dosing and length of treatment.”). 
 286. MULTI-SITE ADULT DRUG COURT EVALUATION, supra note 189, at 51. 
 287. NAT’L ASS’N OF DRUG COURT PROF’LS., RESOLUTION OF THE BOARD OF DIRECTORS ON 
THE AVAILABILITY OF MEDICALLY ASSISTED TREATMENT (M.A.T.) FOR ADDICTION IN DRUG 
COURTS 2 (2011), http://www.nadcp.org/sites/default/files/nadcp/NADCP%20Board%20Statement 
%20on%20MAT. 
 288. WORKGROUP ON SUBSTANCE ABUSE SELF-HELP ORGANIZATIONS, SELF-HELP 
ORGANIZATIONS FOR ALCOHOL AND DRUG PROBLEMS: TOWARDS EVIDENCE-BASED PRACTICE 
AND POLICY 1 (2003). 
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for “approximately 55% of all patients referred to substance abuse 
treatment.”289 Others estimate that “fully a third, probably over 40% of 
AA’s members are—or at least were originally—coerced into attendance 
(by the courts, prisons, employers, and professional diversion pro-
grams).”290 As one author notes, AA is recommended and often required 
by “virtually every facility that provides treatment services within the 
criminal justice system.”291 According to AA’s own 2014 membership 
survey results, 32% of its members were introduced to the group through 
a treatment facility, and 14% through the judicial system directly.292 And 
while “[s]tates vary in the extent to which coercion plays a role in referral 
to treatment,”293 recent estimates put the number of individuals referred 
to substance abuse treatment by the criminal justice system close to 40% 
of total admissions.294 
Our current system of addiction treatment, therefore, presents huge 
challenges to individuals who are seeking treatment, as well as to indi-
viduals who are compelled to obtain that treatment by virtue of partici-
pation in a drug or other specialty court. Even when individuals are re-
quired by courts to receive treatment, much of the treatment they receive 
is not evidence-based and is not delivered in licensed facilities by quali-
fied providers. As one author put it, “[t]he organizational, administrative 
and personnel infrastructures of many treatment programs are fragile 
and unstable.”295 As the above discussion illustrates, however, appropri-
ate addiction treatment options exist and should be delivered through 
the health care system and available to any individual who voluntarily 
seeks to enter treatment.296 But when an individual is compelled to enter 
treatment by a drug court or other specialty court, it is even more imper-
ative that the treatment she receives be effective and evidence-based. 
                                                                                                                                      
 289. McLellan & Meyers, supra note 170, at 765. 
 290. CHARLES BUFE, ALCOHOLICS ANONYMOUS: CULT OR CURE? 7 (1998) (“[M]ore than half a 
million Americans per year are forced into 12-step “treatment” by these same agencies.”). 
 291. Edwards, supra note 167, at 310. 
 292. ALCOHOLICS ANONYMOUS, 2014 MEMBERSHIP SURVEY, http://www.aa.org/assets/en_US/p-
48_membershipsurvey.pdf. 
 293. KATHRYN BATTS ET AL., SUBSTANCE ABUSE & MENTAL HEALTH SERVICES 
ADMINISTRATION, COMPARING AND EVALUATING SUBSTANCE USE TREATMENT UTILIZATION 
ESTIMATES FROM THE NATIONAL SURVEY ON DRUG USE AND HEALTH AND OTHER DATA SOURCES 
49 (2014).  
 294. DEP’T OF HEALTH & HUMAN SERVS., SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES 
ADMINISTRATION, TREATMENT EPISODE DATA SET (TEDS) 2002–2012: NATIONAL ADMISSIONS TO 
SUBSTANCE ABUSE TREATMENT SERVICES 1, 90 (2014) (“For 2012, 1,749,767 substance abuse treat-
ment admissions aged 12 and older were reported to TEDS by 47 states, the District of Columbia, and 
Puerto Rico. Of these, 581,150, or 33.9% of total admissions, were admitted after a referral from the 
criminal justice system.”); see also NAT’L INST. ON DRUG ABUSE (NIDA), PRINCIPLES OF DRUG 
ABUSE TREATMENT FOR CRIMINAL JUSTICE POPULATIONS 18 (2006) (“[A] large percentage of those 
admitted to drug abuse treatment cite legal pressure as an important reason for seeking treatment.”). 
 295. McLellan & Meyers, supra note 170, at 768. 
 296. CASA REPORT, supra note 21, at 227. As the CASA report notes, “[t]his is not an unprece-
dented challenge” and there are other examples of times “where health care practice has lagged be-
hind the science. Only recently, depression was considered a character flaw before the brain science 
was understood and HIV/AIDS was considered a moral scourge before it was seen as a virus that can 
be prevented, treated, managed and perhaps cured.” Id. 
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When courts require individuals to participate in treatment as a condi-
tion of their successful diversion out of the criminal justice system, that 
treatment should be evidence-based and delivered by trained medical 
and mental health professionals. 
Individuals involved in diversion courts should be referred only to 
treatment programs that are administered by a “multi-disciplinary team 
of appropriately trained and credentialed health professionals managed 
by a physician.”297 Nonprofessionals can assist in providing social support 
and encouraging healthy lifestyle changes that reduce the risk of relapse, 
but these individuals should not be primarily or solely responsible for the 
provision of addiction treatment, and their services should not “super-
sede or replace those of the medical team.”298 Once in treatment, individ-
uals should receive appropriate screening for substance use and should 
be provided a full range of treatment options, including psychosocial and 
pharmacological treatments. In particular, drug courts which disallow the 
use of pharmacological treatments for addiction should revisit these re-
strictions based on the medical community’s current understanding of 
addiction as a brain disease and the appropriate role of medication in the 
treatment of addiction. 
As treatment progresses, individuals referred by diversion courts 
should receive diagnosis, stabilization, and acute treatment, all of which 
should be performed or managed by physicians working with a team of 
medical or mental health care providers who are licensed and appropri-
ately trained in addiction treatment.299 While peer support can be an im-
portant component of recovery and individuals should be encouraged to 
take advantage of mutual-support groups and 12-step programs available 
in their communities, this type of support should only be viewed as a 
supplement to individuals who have learned to manage their disease with 
the help of trained medical and mental health professionals.300 Further-
more, addiction treatment facilities should be subject to the same manda-
tory licensing procedures as all health care facilities, and courts should 
refrain from requiring participation in those that are not licensed and do 
                                                                                                                                      
 297. Id. at 228. 
 298. Id. at 212. 
 299. Id. at 228. 
 300. Courts should also continue to be vigilant for the possibility of dual diagnoses and refer indi-
viduals to treatment that can accommodate and appropriately treat the individual. People with drug 
and alcohol use disorders also suffer from higher-than-normal rates of mental health issues, and re-
search has shown that treating depression and anxiety with medication can reduce drinking. But 12-
step programs are not typically equipped to address these issues and group leaders often lack profes-
sional training in addiction and the treatment of dual diagnoses. Furthermore, these individuals will 
often require some type of medication to treat a co-occurring mental illness and some 12-step groups 
“are more accepting than others of the idea that members may need therapy and/or medication in ad-
dition to the group’s help.” Glaser, supra note 11. Because most specialty courts are themselves orga-
nized according to the individual “problems” like drugs, alcohol, or gambling, referral to a compre-
hensive treatment program that is equipped to treat the individual’s underlying addition disease may 
provide the best results. Kerwin et al., supra note 196, at 173 (“[S]uccessful assessment and treatment 
of dual diagnoses increasingly require cross fertilization across substance abuse and mental health 
fields and may even suggest eventual integration of such fields”). 
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not adhere to national accreditation standards that reflect evidence-
based care and treatment for addiction.301 
Individuals suffering from substance use and abuse have historically 
been stigmatized and underserved, and there is an urgent need for “drug 
court judges and staff to adopt medically sound practices in an area of 
drug dependence that benefits from decades of scientific research.”302 
Part of the promise of scientific developments in the diagnosis and 
treatment of addiction is the reversal of the pervasive social stigma relat-
ed to addiction and individuals suffering from addiction, and a resulting 
improvement in available and effective treatment options.303 One way in 
which drug and other specialty courts can be part of the transformation 
of the public perception of addiction, as well as the integration of addic-
tion treatment into mainstream medicine, is through embracing of evi-
dence-based strategies for the treatment of addiction. Moreover, by 
adopting these treatments more readily and providing more opportuni-
ties for drug court participants to receive evidence-based treatment, drug 
courts can dramatically improve treatment outcomes for participants. 
V. CONCLUSION 
Drug courts have not kept pace with advancing scientific knowledge 
about addiction and evidence-based treatment for the disease of addic-
tion. Instead of receiving evidence-based treatment, most drug court par-
ticipants are referred to mutual-support groups and programs based 
largely or entirely on 12-step principles. Mutual-support groups, while 
well-intentioned and helpful as a supplement to evidence-based addic-
tion treatment, are not a substitute for scientifically valid addiction 
treatment and should not constitute the primary form of medical assis-
tance received by drug court participants. Drug courts can be part of the 
transformation of the public perception of addiction, as well as the inte-
gration of addiction treatment into mainstream medicine by incorporat-
ing and endorsing evidence-based strategies for the treatment of addic-
tion, including psychosocial and pharmacological treatments. Moreover, 
by adopting these treatments more readily and providing more opportu-
nities for drug court participants to receive evidence-based treatment, 
drug courts can dramatically improve treatment outcomes for partici-
pants. 
  
                                                                                                                                      
 301. Kerwin et al., supra note 196, at 180. 
 302. Joanne Csete & Holly Catania, Methadone Treatment Providers’ Views of Drug Court Policy 
and Practice: A Case Study of New York State, 10 HARM REDUCTION J. 1, 7 (2013). 
 303. Dackis & O’Brien, supra note 28, at 1435 (“The development of treatments that dramatically 
improve clinical outcome should reverse social stigma and justify an expanded care delivery system.”). 
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